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Sommario 
 
Lo studio parte dall’osservazione che i pazienti pediatrici affetti da leucemia, presentano un 
interessamento osseo ancora prima della diagnosi e che persiste durante e dopo la terapia.  
La principale via regolatrice del metabolismo osseo è quella del Receptor Activator Nuclear 
Factor Kappa B Ligand (RANKL), anche noto come CD254. Questo ligando esiste sia in 
forma solubile sia di membrana (CD254). Il CD254 è espresso soprattutto dagli Osteoblasti 
(OBs), le cellule responsabili della formazione dell’osso, mentre il suo recettore, RANK, 
dagli Osteoclasti (OCs), le cellule deputate al riassorbimento. Gli osteoclasti degradano l’osso 
dopo l’attivazione attraverso il legame del RANKL. Altre cellule possono esprimere il 
RANKL e l’alta espressione del RANKL è associata alla capacità delle cellule di indurre 
osteolisi. L’analisi al citofluorimetro ha dimostrato che l’espressione della forma di 
membrana CD254 è up-regolata nei pazienti all’esordio B LLA Common rispetto ai controlli 
fuori terapia o a fine mantenimento. Mediante esperimenti di co-cultura è stata studiata la 
capacità dei blasti di influenzare il differenziamento dei precursori degli osteoclasti. E’ stata 
valutata quindi la capacità dei precursori CD14+ di fondersi a formare una cellula 
multinucleata, l’osteoclasto maturo, il quale in seguito diventa attivo e in grado di degradare 
la matrice ossea. La capacità di degradazione dell’osso è stata valutata usando una linea 
cellulare leucemica (SEM) esprimente il CD254, messa in co coltura con i CD14+. Le cellule 
coltivate in un terreno contenente frammenti di osso sono state in grado di degradare il 
substrato osseo. E’ stata poi valutata la capacità di multinucleazione da parte dei blasti da BM 
degli esordi ed esprimenti CD254 rispetto a quella dei controlli. Si è visto che l’alta 
espressione del RANKL sui blasti CD19+ dei pazienti alla diagnosi induce multinucleazione 
dei CD14+. Inoltre studi di Gene Expression Profile (GEP) sono stati fatti per valutare se ci 
fosse un’alterazione dei geni coinvolti nell’osteoclastogenesi e nell’osteopetrosi e alcuni di 
questi sono risultati down regolati in modo significativo.  
In questo network d’interazioni cellulari abbiamo voluto studiare un aspetto della 
comunicazione cellulare che riguarda le Microvescicole circolanti o “Extracellular Vesicles” 
(EVs). Le EVs sono state caratterizzate al citometro per l’espressione di marcatori di leucemia 
(CD19), piastrine (CD61) e per il metabolismo osseo (CD254). I risultati indicano che la 
produzione di EVs negli esordi dei pazienti B ALL è down regolata e che solo poche 
vescicole esprimono il CD19. Nel complesso questi dati suggeriscono che esiste un 
coinvolgimento diretto dei blasti nella via che regola il metabolismo osseo e che i blasti 
possono influenzare gli osteoclasti. 
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Summary 
 
 
This study begins with the clinical observation of muscolo-skeletal involvement in leukaemia.  
Bone metabolism alterations have been reported before diagnosis, and persist during therapy 
and follow up. The Receptor Activator Nuclear Factor Kappa B Ligand (RANKL), also 
known as CD254, represents the major pathway that regulates bone metabolism. This ligand 
can exist either as a soluble form either as membrane form (CD254). The ligand is expressed 
mainly by bone forming cells osteoblasts (OBs) and its receptor RANK is expressed by bone 
resorbing cells osteoclasts (OCs). Upon the binding of the ligand to its receptor osteoclasts 
precursor are induced to fuse into a multinucleate cell, able to resorb bone substrates. Flow 
cytometry analysis showed that membrane CD254 was up regulated in B ALL patients at 
diagnosis compared with control patients (Stop therapy and maintenance). 
Co-colture of CD14+ osteoclast precursors have been performed in order to assess the ability 
of CD14+ to fuse into multinucleate cells and eventually to resorb bone substrate. We 
evaluated the ability of a leukaemia cell line SEM, showing CD254 expression to influence 
CD14+ cells to differentiate and digest bone. Subsequently we co-coltured primary bone 
marrow cells from patients at diagnosis and controls and the ability to induce multinucleation 
of CD14+ cells were evaluated. Gene expression profile (GEP) was performed in order to see 
if RANKL involved pathways were altered in patients at diagnosis. We found that 
osteoclastogenic pathway, and osteoclast specific genes involved in osteopetrosis were down 
regulated.  
In this context of interaction we decided to focus on the cell communication through 
circulating membrane vesicles. Known with the generic term of extracellular vesicles (EVs), 
those can be isolated from the peripheral and bone marrow plasma. Here they have been 
isolated and analysed by flow cytometer for specific B leukemic (CD19), platelets (CD61) 
and bone (CD254) markers. The results showed that the overall number of EVs in peripheral 
blood plasma from diagnosis was reduced compared to the controls. Only few CD19+ 
vesicles were present in the peripheral blood plasma of diagnosis.   
In conclusion this study highlights the importance of the interaction between blasts cells and 
the bone metabolism, suggesting leukaemia can actively influence osteoclasts precursors. 
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1. INTRODUCTION 
 
1.1. Acute lymphocytic leukaemia: an overview   
Acute lymphocytic leukaemia (ALL) is a clonal B and T disorder of the neoplastic cells 
characterized by an increase of slow proliferating cells in the bone marrow and other 
lymphoid organs. This gives rise to an accumulation of circulating monoclonal cells that 
escape the normal cellular process involved in cell cycle cycling, senescence and apoptosis. 
ALL is the most common cancer diagnosed in children and representing about 25% of cancer 
diagnoses among children younger than 15 years (Howlander et al., 2013). Dramatic 
improvements in survival have been achieved in children and adolescents with cancer. For 
ALL, the 5-year survival rate has increased approximately to 90% for children younger than 
15 years and to more than 75% for adolescents aged 15 to 19 years (Smith et al., 2014; 
Hunger et al., 2005). Childhood and adolescent cancer survivors require close follow-up 
because cancer therapy produce side effects that may persist or develop months or years after 
treatment. Risks of ALL have been identified. The primary risk factors for ALL include 
prenatal exposure to x-rays, postnatal exposure to high doses of radiation. Also genetic 
conditions associated to inherited disorders as Down syndrome, Neurofibromatosis (Stiller et 
al., 1994), Shwachman syndrome (Wood et al., 1980), Ataxia telangiectasia (Moriyama et al., 
2015) might induce leukemia. Inherited genetic polymorphisms and carriers of a 
constitutional Robertsonian translocation (Li et al., 2014). Development of ALL is in most 
cases a multi-step process, with more than one genomic alteration required for leukaemia 
disease to develop. In some cases of childhood ALL, the initial genomic alteration appears to 
occur in utero (Taub et al., 2002). ALL characterized by specific chromosomal abnormalities, 
with blood cells carrying at least one leukemic genomic abnormality at the time of birth, can 
acquire additional genomic changes postnatally (Bateman et al., 2010). Genomic studies of 
identical twins with leukaemia further support the prenatal origin of some leukaemias 
(Greaves et al., 2002). Today is accepted the hypothesis that additional postnatal genomic 
changes are needed for the development of this type of ALL and that in most cases in which a 
leukaemia-associated alteration is present at birth, the additional leukemogenic genomic 
changes do not occur and no leukaemia develops. Among children with ALL, more than 95% 
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attain remission, and approximately 80% of patients aged 1 to 18 years with newly diagnosed 
ALL treated on current regimens are expected to be long-term event-free survivors (Gaynon 
et al., 2010). Despite the treatment advances noted in childhood ALL, numerous important 
biologic and therapeutic questions remain to be answered before the goal of curing every 
child with ALL with the least associated toxicity can be achieved. Treatment related skeletal 
complications such as osteonecrosis significantly contribute to short and long term disability 
in many survivors of pediatric hematological malignasies (Moab and Halton, 2014). In about 
80% to 85% of children with ALL, the leukaemia starts in B cells. There are several subtypes 
of B-cell ALL as shown below (immature to mature forms): 
Early precursor B (early pre-B) ALL (also called pro-B ALL) 
Common ALL 
Pre-B ALL 
Mature B-cell ALL (also called Burkitt leukaemia). This type is rare, accounting for only 
about 2% to 3% of childhood ALL. It is essentially the same as Burkitt lymphoma and is 
treated differently from most leukaemias. 
Infant leukaemia” generally refers to acute lymphoblastic leukaemia (ALL) or acute myeloid 
leukaemia (AML) diagnosed in a child before 1 year of age. A high proportion of acute 
leukaemias occurring in infants are characterized cytogenetically by balanced chromosomal 
translocations involving the mixed lineage leukaemia (MLL) gene at chromosome 11q23, 
known as t(4:11).  
 
1.2. Clinical Presentations  
The typical and atypical symptoms and clinical findings of childhood ALL have been 
published (Onciu et al., 2014). Of relevance skeletal abnormalities are commonly seen in 
children and adolescent with leukaemia. Orthopedic surgeons frequently misdiagnose 
pediatric leukaemia with musculoskeletal condition and patients receive a significant delay in 
diagnosis of acute leukaemia. Blood examinations show: no blasts, low platelets, low 
hemoglobin, and high C- reactive protein. Low bone turnover and osteopenia are the major 
manifestation of bone metabolism involvement (Kobayashi et al., 2005). These abnormalities 
can mimic several orthopedic pathologies at presentation, with a variable delay in the correct 
diagnosis. These manifestations occur before diagnosis. At presentation and prior initiating 
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chemotherapy serum specific bone formation markers are low. These include osteocalcin, 
type I collagen carboxy terminal propetide, and bone specific alkaline phosphatrase are low. 
Similarly parameters measuring bone degradation are low, as urinary telopeptide and type I 
carboxy terminal telopetptide. Thus both bone formation and bone resorption markers seems 
to be altered suggesting an overall low bone turnover state (Halton et al., 1995; Rogalsky et 
al., 1986; Sorva et al., 1997; Moab and Halton, 2014).  
 
1.3. Muscolo-skeletal system alterations in acute lymphocytic 
leukaemia 
The leukemogenic characteristics of blasts are explained by their intrinsic properties and by 
extrinsic factors due to the altered cross talk with their microenvironment. Normal 
haematopoiesis requires complex bidirectional interactions between the bone marrow 
microenvironment (niche) and hematopoietic stem cells (HSCs). A spectrum of signaling 
pathways can regulate the interactions of HSCs with the niche (Lane et al., 2009; Lane et al., 
2011). Bone marrow components of the normal haematopoietic stem progenitor cells 
(HSPCs) niche may play an essential role in the disease progression and deregulation of 
normal haematopoiesis occurring during the leukemogenic process (Sipkins et al., 2005; 
Burger et al., 2007). Leukemic cells alter osteoblastic and osteoclastic cell function resulting 
in measurable skeletal changes, which may impair normal hematopoiesis  (Frish et al., 2011). 
However, the cellular and molecular players, which contribute to a favorable leukaemia 
microenvironment, remain poorly understood. HSPCs are thought to reside in specific niches; 
cavities within the BM formed by specialized bone resorbing cells, the osteoclast (OCs) 
derived from monocytes/macrophage lineage. Osteoblasts (OBs) bone generating cells, arise 
from mesenchimal stem cells and together with other cells types like vascular endothelial 
cells or reticular cells they provide to HSPCs a nurturing microenvironment to grow (Calvi et 
al., 2003; Zhang et al., 2003; Arai et al., 2004; Stier et al., 2005; Adams and Scadden, 2006; 
Lymperi et al., 2011). The ability of leukaemia cells to alter the niche components in the bone 
marrow is well documented and the effects are well described in acute myelocytic leukemia 
(AML) models: in mouse primary stromal dysfunction of osteoprogenitors can cause 
secondary neoplastic disease as myelodisplasia and secondary leukaemia (Raaijmakers et al., 
2010), mouse leukaemia stem cells (LSC) engraft into the hematopoietic microenvironment 
(Lane et al., 2011), similarly human LSC home to and engraft within the osteoblast-rich area 
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of the bone marrow, both acquiring chemotherapy resistance (Ishikawa et al., 2007). 
Analogous results were observed in an in vitro model of acute lymphoblastic leukaemia 
where mesenchimal secretion of asparagine synthetase conferred resistance to asparaginase 
drug (Iwamoto et al., 2007). Furthermore leukaemia cells have direct effects on bone 
metabolism altering host formation and turnover in AML mouse (Frish et al., 2011). 
Imbalance of bone remodeling factors has been suggested to be involved in HSPC 
mobilization in human (Li et al., 2013). In steady state conditions, only low levels of HSPCs 
egress to the circulation. Treating with granulocytes colony stimulating factor (G-CSF) breaks 
the balance between HSPCs and bone lining osteoblasts causing HSPCs mobilization (Li et 
al., 2013). In concomitance with the G-CSF treatment it is possible to observe a clinical 
phenomenon known as bone remodeling process. Accompanied by bone pain (Vial et al., 
1995) this reflects the dramatic reduction in bone turnover. Continuous G-CFS treatment to 
prevent neutropenia causes osteopenia, a decrease of bone mineral density and vertebral 
compression fractures (Bishop et al., 1995; Dale et al., 2003).  
 
1.4. The Receptor Activator Nuclear Factor NF-kB Ligand 
(RANKL) pathway in bone metabolism 
One of the most relevant pathways involved in bone homeostasis is the axis mediated by 
Receptor Activator Nuclear Factor NF-kB Ligand or RANKL (also known as TNSF11, 
TRANCE, OPGL, CD254) and its receptor RANK. RANKL is a member of the TNF super 
family and it is synthesized and expressed on cell membrane of bone marrow stromal cells 
and osteoblast. However RANKL expression can be detected in other tissues as spleen, 
placenta stomach, thyroid lung, brain, thymus, lymph nodes, and finally on osteoclasts and 
peripheral blood lymphocytes (Kartsogiannis et al., 1999; Anderson et al., 1997). RANK is 
the receptor for RANKL and it is known to be essential for osteoclasts as it is required for 
their differentiation, maturation and survival (Kong et al., 1999). Osteoprotegerin (OPG) is a 
decoy receptor for RANKL, thus inhibiting binding to osteoclasts and preventing 
osteoclastogenesis differentiation. RANK is expressed by dendritic cells, fibroblast, B and T 
cells, osteoclasts (reviewed in Theoleyre et al., 2004). Co stimulatory signal to the 
RANKL/RANK interaction are represented by immune receptor tyrosine-based activation 
motif  (ITAM) bearing adapter proteins, as DAP12 or Fcε receptor I γ chain (FcRγ). Both are 
required for osteoclast maturation and activation (Mocsai et al., 2004; Humphrey et al., 
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2005). Upon activation a tyrosine phosphorylation on ITAM domain recruits SYK kinase, 
which in turn initiate a transduction cascade including several pathways as phospholypase C γ 
(PLCγ), calcium mobilisation, phosphatidylinositol-3 kinase (PI3K), RAS, nuclear factor kB 
(NFkB) and nuclear factor for activation of T cells (NFAT) (Shinohara et al., 2008). DAP12 
associates to multiple cell surfaces activating receptor depending on cell type like CD300d 
(Lanier et al., 2009). Myeloid cells and above all natural killer NK highly express DAP12. 
Among lymphocytes, B cells can also express it. DAP12 is involved in innate immunity 
driven by NK and myeloid cells. Furthermore is involved in B cell dependent adaptive 
immune response. DAP12 deficient mice B cells and B cells from patients with a recessive 
genetic disorder named Nasu Hakola resulting fron loss of DAP12 are both characterized by 
abnormal increased responses through Toll like receptor TLR9. Thus in physiological 
conditions DAP12 act as negative regulator of B cell proliferation upon induction of adaptive 
immunity (Nakano-Yomizo et al., 2011). Dap12-/- mice show a mild osteopetrotic phenotype 
whereas double mutant Dap12-/- FcRγ -/- are severely osteopetrotic. Integrin ανβ3 is in the 
same signalling complex in a linear sequence. In absence of these three players the 
osteopetrotic phenotype is very strong, with a defect in the osteoclasts ability to resorb bone 
because lacking of cytoskeleton organization (Zou et al., 2014). A role of RANKL/RANK 
pathway in disease patho-physiology of chronic leukaemia and multiple myeloma is already 
known, as well as for metastatic spread of solid tumors (Jones et al., 2006; Palfox et al., 2012; 
Tan et al., 2011). RANKL/RANK have been reported to regulate immune response NK 
mediated in acute myeloid leukaemia (Schmiedel et al., 2013). In pathological conditions 
RANKL is over expressed in primary malignant bone tumours, as osteosarcoma, 
chondrosarcoma, giant cell tumour (Grimaud et al., 2003) and multiple myeloma (Giuliani et 
al., 2001). 
 
1.5. Defective osteoclasts and osteopetrosis in human 
Osteoclasts, the only bone-resorbing cell, arise from the myeloid lineage, including 
macrophages and monocytes. Upon activation, the osteoclast's plasma membrane attach to the 
underlying bone forming the sealing zones, belts of specialized adhesion structures called 
podosomes. Attachment to the bone matrix is allowed by integrin receptors, such as αvβ3. 
The osteoclast releases hydrogen ions through the carbonic anhydrase into the resorptive 
cavity, acidifying and aiding dissolution of the mineralized bone matrix into Ca2+, H3PO4, 
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H2CO3, water and other substances. The mobilization of the mineral phase opens the way to 
hydrolytic enzymes, such as members of the cathepsin and matrix metallo-protease (MMP) 
groups, which are released to digest the organic components of the matrix. These enzymes are 
released into the compartment by lysosomes. Among hydrolytic enzymes, cathepsin K is of 
most importance. Cathepsin K is secreted from the ruffled border into the resorptive pit. 
Cathepsin K transmigrates across the ruffled border by intercellular vesicles and is then 
released by the functional secretory domain. Within these intercellular vesicles, cathepsin K, 
along with reactive oxygen species generated by TRAP, further degrades the bone 
extracellular matrix (Cappariello et al., 2014). RANKL and macrophage colony simulating 
factor M-CSF are required during osteoclast differentiation. In human osteoclast defects 
represent a rare and hereditable bone disorder characterized by high bone mass due to 
insufficient activity of osteoclasts. Two major clinical osteopetrosis forms have been 
identified; the autosomal recessive osteopetrosis (ARO) often lethal in early childhood, and 
the second form autosomal dominant osteopetrosis ADO II, known as Albers-Schonberg 
disease or marble bones, seen in adults. The first form is caused by homozygous mutation of 
TCIRG1 gene that impairs osteoclast acid secretion. The latter can be due to a homozygous 
mutation to CLCN7 and OSTM1, which form a molecular complex. ADO II is associated with 
serious clinic complications, such as fractures, delayed fracture healing and osteomyelitis 
(Del Fattore et al., 2008; de Vernejoul et al., 2010). Coudert (Coudert et al., 2014) performed 
a transcriptomic analysis by comparing gene expression profile of ADO II with healthy 
donors. They found among other genes that SERPINE2 and WARS were differentially 
expressed and suggested those to be part of the ADO II phenotype, together with the already 
characterised function of CLCN7 and its partner OSTM1. SERPINE2 is involved in the 
removal of non-collagenous proteins that are present in the non-mineralized bone matrix: it 
was also significantly down regulated in ADO II patients. Aminoacyl-tRNA synthetases 
catalyze the aminoacylation of tRNA by their cognate amino acid. Tryptophanyl-tRNA 
synthetase (WARS) catalyzes the aminoacylation of tRNA(trp) with tryptophan and is 
induced by interferon. Tryptophanyl-tRNA WARS was significantly down regulated in ADO 
II (Coudert et al., 2014).  
The functional activity of the bone system are ensured not only by the major players as OCs 
and OBs, but several other accessory cells, not directly involved in the formation or 
degradation of the skeleton support and cooperate to ensure the physiological bone 
homeostasis.  
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1.6. Bone homeostasis maintenance: old and new players 
Bone homeostasis relays on the functional activity of OBs and OCs. They work in concert to 
ensure the correct balance between bone formation and degradation. In the niche context the 
role of stromal and mesenchimal stem cells is well known. However among these a rare 
population exist which is represented by Megakaryocytes (MKs), responsible for platelets 
release, and also involved in the maintenance of the bone marrow niche through the 
expression of components of the basement membrane, necessary components of the extra 
cellular matrix microenvironment (Malara et al., 2014). MK can produce RANKL and OPG, 
and their expression is modulated by oestrogen (Bord et al., 2004; Bord et al., 2005). 
Megakaryocytes grown in co-colture with osteoblasts were able to increases osteoblastic OPG 
synthesis while suppressing RANKL expression, demonstrating that in vitro MK have a direct 
effect on bone forming cells (Bord et al., 2005). Mice with deletion of p45 NF-E2 results in 
the arrest of megakaryocytes differentiation and are characterized by high mass phenotype. In 
these mice both OCs and OBs number were increased and they were functional. Furthermore 
the increased bone mass was observed only in bony sites of hematopoiesis. This impairment 
was due to a missed cross talk with OBs rather than OCs (Kacena et al., 2004). An in vitro 
study showed that MK could also influence OCs precursor. Co-colture of mature MKs with 
PBMC CD14+ cells inhibited the formation of OCs reducing their number and, affecting their 
functionality (Beeton et al., 2006). Mice in which OBs function is ablated or overexpressed 
both resulted in early blocks of B cell development (Wu et al., 2008). Furthermore 
haematopioetic cells are involved in the regulation of the bone homeostasis, directly and 
indirectly influencing bone cells, specifically the osteoclasts digesting cells. 
 
1.7. B-lymphocytes and the bone players: a tight relationship  
B-lymphocytes are in close proximity with the bone cells, osteoblasts and osteoclasts. 
Perturbation of B lymphopoiesis affects the bone mass, and on the other side alteration of 
bone homeostasis affects B lymphopoiesis. B cell development occurs within the vascular 
microenvironment of the BM. Stromal cells, and OBs produce factors like chemokine C-X-X 
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motif chemokine 12 (CLCX12), stem cell factors (SCF), IL7, RANKL and OPG, which are 
critical for early B cell development (Manilay and Zouali 2014; Toraldo et al., 2014). 
RANKL and osteoprotegerin produced by stromal cells are also important for B cells 
development specifically at the pre-B to immature transition. Mesenchimal and OBs cells 
contributes to support all developmental transition in B lymphopoiesis through local secretion 
of B lymphocytes survival factors as vascular cell adhesion molecule-1 (VCAM-1)-mediated 
adhesion and in situ secreted IL7 and CXCL12 (Egawa et al., 2001; Miller et al., 2002).  
B lymphopoiesis is a highly regulated process which starts from the progenitors in the fetal 
liver, move to the BM, to end the maturation in the secondary lymphoid organs (SLOs), such 
as the spleen and lymphonodes. After B cells mature in the bone marrow, they migrate 
through the blood to SLOs, where receive a constant supply of antigen through circulating 
lymph. At the SLOs, B cell activation begins when the B cell binds to an antigen via its BCR. 
Only after the mature B cell meet the T cell derived helper can terminally differentiate into 
immunoglobulin (Ig)- secreting plasma cell (Ghia et al., 2010). The B cell development is 
organized around the assembly of a functional B-cell receptor (BCR) through a process of 
gene rearrangement called V(D)J recombination. The molecular players responsible for the 
correct rearrangements to have a functional BCR are different transcription factors, required 
at specific time of the different developmental transitions. Several genes are involved in B 
cell maturation (Figure 1). Of this Pax5 is specifically required for B cell development at the 
pro B to pre B transition. Pax5 codes for the transcription factor B cell lineage specific 
activator protein (BSAP). It is expressed exclusively in the B-lymphocytes lineage extending 
from pro-B cells to mature but not to the terminally differentiated plasma cells. Pax5 deletion 
causes among various deleterious effects the arrest of all B cell development beyond the early 
pro B stage. 
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Figure 1: B cell differentiation and its transcription factors. (From Horowitz et al., 2008). 
These pro B cells have the ability to be maintained in an undifferentiated phase if grown in 
presence of IL7, the removal of which cause these cells to differentiate into multiple 
hematopoietic phenotypes including osteoclasts. Furthermore in Pax5-/- pro B cells, treatment 
with MCS-F and RANKL can induce the formation of osteoclasts (Yoshida et al., 1990).  
Mice with deletion of Pax5 are osteopenic due to an increase of osteoclast number, and not to 
the lack of B cells (Horowitz et al., 2004). In Pax5 deficient mice the alteration are specific 
for osteoclast and B cells, and not other haematopoietic compartments are involved (Yoshida 
et al., 1990). Pax 5 gene is responsible for the correct activation and suppression respectively 
of B cell lineage specific genes and myeloid precursors. Uncommitted haematopoietic 
progenitors including Pax5-/- pro B cells express genes of different lineages (Nutt et al., 
1999; Miyamoto et al., 2002). At commitment Pax5 activates target genes as components of 
the pre BCR. Pax5 depressed genes include among others RANKL, MCSF-R and Notch1 
with the result that B cells are not anymore responsive to myeloid signals (Nutt et al., 1999). 
During B cell differentiation the transcriptional activity responsible for activation and 
repression of specific genes is accompanied by cytokines produced by stromal cells, which 
became essentials in the transition phase. Interleukin 7 has a pivotal role in B lymphopoiesis 
at the transition from pro B cells to pre B cells. IL-7 overexpressing mice have expanded 
number of pre B cells, and increased bone resorption, probably because IL-7 stimulated B 
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cells expresses RANKL and can thus activate osteoclast-resorbing activity (Myamura et al., 
1997). Another mice model that highlight the importance of the cross talk between OCs and B 
cells is represented by oc/oc mice, which are osteopetrotic due to the absence of resorbing 
osteoclasts caused by a mutation in tcgr1 gene. Those mice behave similarly to IL7-/- models, 
presenting the arrest at the transition between pro B and pre B. In these mice IL-7 injection 
caused the partial rescue of B lymphpoiesis by engaging a population of bone marrow cells 
(described by Blin Wakkach et al., 2004) B220+ CD11b+ into B lymphocytes through the 
induction of Pax5 and the inhibition of the myeloid lineage specific genes (Blin Wakkach et 
al., 2006). This model and the phenotype observed showed that a mixed lineage population 
exist in the BM and that factors as IL7 can revert the myeloid lineage phenotype towards the 
B lymphoid one. IL-7R deficient mice have suppressed B cell development and increased 
bone mineral density (Peschon et al., 1994). B cell autonomous RANKL expression is also 
important for B cells development as shown in RANKL knock out (KO) mice. Osteopetrotic 
RANKL KO mice have a clear block at the haematopoiesis between the pro and pre B cells. 
RANKL deficient mice show severe osteopetrosis, because no osteoclasts are present and in 
turn no bone marrow spaces can be formed. B cell differentiation is arrested at the pro B pre 
B stage. Number of cells is reduced and an intrinsic defect exists in these pre B cells (Kong et 
al., 1999; Kim et al., 2000). Another informative model is represented by an established pre B 
cell line named preBR. This cell line was able to differentiate into immature B cells in vitro 
after removal of IL7 from the colture medium (Kato et al., 2003). RANKL expression was 
dependent upon IL7 and transfectant overexpressing RANKL were induced to proliferate 
through inhibition of the G1 arrest. RANKL also increased the percentage of cells S/G2/M 
phase. Physiologically RANKL expression was thus shown to be restricted to the pre B cell 
stage (Kato et al., 2003). Oestrogen deficiency mimics the IL7 overexpression, causing an 
increased B lymphopoiesis. Ovariectomy mice and subsequent oestrogen withdrawal, resulted 
in marked accumulation of B220+ pre B cells, which activity was linked to the up regulated 
bone resorbing activity of osteoclasts (Miyamura et al., 1997). Figure 2 summarize the 
cytokines requirements for B cell development in mice as reviewed by Manilay (Manilay and 
Zouali, 2014). Injection of IL7 partially restores B lymphopoiesis but not completely, 
indicating that not only the niche but also cell intrinsic factors are involved in interaction with 
OCs.  
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Figure 2: Cytokine requirements during B cell differentiation in mice. Adapted from 
Maniklay and Zouali, 2014.   
Treatment with zoleodronic acid (ZA) in wild type mice could induce mild osteopetrosis 
affecting B cell development. The effect of ZA seemed to be linked to the microenvironment 
modification rather then a B specific phenotype. B cells progenitors were less retained in the 
bone marrow and were homed instead in other organs as the spleen. Histological analysis of 
ZA mice femora confirmed trabecular region with mineralised bone matrix, and disorganised. 
Tartarate resistant acid phosphatase (TRACP) showed a large number of OCs not attached to 
the bone surface. ZA effect was thus decreasing OCs resorbing activity because they loss their 
adhesion ability, rather than to a decrease in OC number (Mansouret al., 2011). ZA treated 
mice showed that B cell compartment was affected and no others. Mansour (Mansour et al., 
2011) suggested that the decreased cell number of mature B cells could be due to an impaired 
retention and mobilisation of B cell precursors outside the bone marrow. In this frame 
osteoclasts are arising as bone cells strongly connected to the B cells and indeed they share 
transcription factors involved in their maturation and differentiation. As described above the 
B cells and osteoclasts cross talk is made of diverse modes of communication. A novel 
mechanisms of cell-cell communication relays on extracellular vesicles as it will be described 
in the next section.  
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1.8. Cell to cell communication: extracellular vesicles as carriers of 
information 
Haematopoietic precursors from which osteoclasts and B cells originate resides in the bone 
marrow niche.  The niche has a physical meaning but it is also made of a complex net of 
interactions. Different cell populations contribute to maintain suitable condition for HSPCs to 
grow and develop. In this frame intracellular communication between cells and their 
microenvironment is essential for its functionality and integrity. Beyond cell-cell interactions 
cross talk between niche components is traditionally viewed as mediated by soluble factors; 
however new contribution of shed membrane vesicles has been recently appreciated 
(Ratajczak 2006; Mause and Weber, 2010).  
 
 
 
Figure 3: Schematic representation of the extracellular vesicles. Major populations 
include exosomes, microvesicles and apoptotic bodies (From Gyorgy et al., 2011). 
 
Secreted membrane-enclosed vesicles, collectively called extracellular vesicles (EVs), which 
include exosomes, ectosomes, microvesicles, microparticles, apoptotic bodies and other EV 
subsets, encompass a very rapidly growing scientific field in biology and medicine. They 
differ for their biogenesis and for their size. Exosomes are budded out after plasma membrane 
fuses with multivesicular bodies (MVBs), which are endosomal structures carrying multiple 
vesicles in the cytosol (Raposo et al., 2013). The released exosomes are homogenous vesicles, 
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of around 40-100 nm in diameter (Simons et al., 2008). While it is known that exosomes 
contain endosomal proteins such as tetraspanins (CD9, CD63), Alix, and TSG101, and are 
used as exosomal markers (Simons et al., 2009; Simpson et al., 2008), for microvesicles, 
there are not yet identified common markers. Microvesicles are also known as ectosomes, 
shedding vesicles, microparticles, and plasma membrane-derived vesicles, and originate from 
the plasma membrane by outward budding and fission (Murilidharan-Chari et al., 2010). 
Microvesicles are about 50-1.000 nm in diameter, but their density is undefined 
(Murilidharan-Chari et al., 2010). The most important difference between exosomes and 
microvesicles is in their biogenesis. Microvesicles are generated by budding from the plasma 
membrane and thus resemble the plasma membrane composition of the parent cells. On the 
other hand, exosomes generated by inward budding and fission with MVBs, are composed of 
various cytosolic proteins related to endolysosomal pathways (Figure 3). Exosomes and 
microvesicles carry specific markers, but those markers are not completely unique to 
distinguish them from each other. EVs interact with recipient cells by ligand-receptor 
interactions, fusion, and internalization via receptor-mediated endocytosis or 
macropinocytosis (reviwed by Yoon et al., 2014). In this study we will focus only on a group 
of membrane bodies with diameter comprised between 100 and 1000 nm, and we will refer to 
them simply as extracellular vesicles (EVs). 
Extra-vesicular bodies are surrounded by double layer cell membrane, which are released by 
cells, both in vivo and in vitro, in physiological and pathological conditions. In physiological 
conditions the shedding of EVs accompanies cell activation and growth. In pathological 
conditions such as solid tumours their content promotes progression and metastasis of the 
disease (Ratajczak et al., 2006; Peinado et al., 2011; Ghasemi et al., 2013). EVs are shed 
from a variety of cell types. They are present in body fluids such as blood, urine, ascites 
(Graves et al., 2004; Piccin et al., 2007; Smalley et al., 2008; Taylor and Gercel-Taylor, 
2008). Recently it has been recognized their potential as indicators in the diagnosis, prognosis 
and follow up of different diseases and in compromised health conditions where the level of 
EVs bodies is generally increased (van Doormal et al., 2009; Fleissner et al., 2012). 
Fast growing cells tend to release more EVs, than slow growing cells. The increase in EVs 
release can be induced by several factors, as cell activation, hypoxia and radiation, oxidative 
injury, complement cascade, upon cytoplasmic calcium released and by degradation of the 
membrane skeleton (reviwed by Ratajczak et al., 2006). 
EVs packaged with bioactive molecules as miRNAs, mRNA, proteins have been reported to 
be secreted by differentiated cells and tumor cells (Cocucci et al., 2009; Ratajczak et al., 
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2006; Ghosh et al., 2010). It has also been suggested that extra-vesicular bodies are involved 
in stem cell plasticity, being able to modulate specific cells at different cycling phases (Alliota 
et al., 2010). 
In lymphocytic leukaemia EVs were suggested to modulate the hematopoietic niche, and 
found at increased levels in plasma of B-cell chronic lymphocytic leukaemia (CLL) patients. 
Early-stage disease is characterized by predominantly platelet derived extra-vesicular bodies. 
With the progression of the disease the number of B-lymphocyte–derived EVs increases 
compared to platelet ones. These extra-vesicular bodies are able to modulate stromal cells. In 
CLL the EVs level was increased compared to control patients. The secreted EVs were able to 
modulate the in vitro the bone marrow stromal cells, causing the activation of the 
AKT/mammalian target of rapamycin/p70S6K/hypoxia-inducible factor 1α axis, with the 
production of a pro-leukemic factor, the vascular endothelial growth factor. In addition EVs 
were responsible of the activation of the β catenin pathway. EVs from CLL cells were thus 
able to transfer phospho receptor tyrosine kinase Axl directly to the stromal cell (Ghosh et al., 
2010).  
These data highlight the importance of EVs in the tumor progression and their ability to 
modulate the microenvironment. The world of extracellular vesicles is a fast growing field 
with multiple applications. Today we still lack standardization of the isolation and absolute 
quantification procedures. Notably their availability in diverse body fluids might provide an 
easy accessible source of biomarkers to use in clinic, making them very interesting.  
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2. Aim of the study 
 
Leukaemia disease and the skeleton are physically connected within the bone marrow. Bone 
involvement and its alterations in leukaemia are well documented. However the mechanism 
responsible of this phenomenon is not well known. The low bone turn over is the major 
manifestation at diagnosis, even before blast crisis. Acute lymphocytic leukaemia mimics 
several orthopaedic pathologies, causing a delay in the correct diagnosis. Furthermore the 
therapy aggravates the bony phenotype with consequence in the long-term survival of young 
patients. Beyond the protection that the skeleton represent for the hematopoietic compartment 
there is a net of interactions that in both directions ensures the physiological grow of 
lymphocytes and bone cells, and alteration of this homeostasis causes at the same time the 
bone or the lymphopoiesis imbalance. RANKL pathway is a shared key involved in the 
regulation of both compartments. We asked if RANKL is altered in paediatric B ALL 
diagnosis, and if RANKL expression on blasts cells had a functional meaning. Specifically if 
B ALL blasts were able to influence the osteoclast cells, which carries the RANK receptor for 
RANKL. Furthermore we characterised peripheral blood and bone marrow extracellular 
vesicles in controls patients and compared them to the peripheral blood population at 
diagnosis analysing leukaemia and bone specific marker RANKL. This study wanted to 
address the possibility that blasts actively influence the bone marrow environment, 
specifically bone resorbing cells, and possibly beyond known interaction modes trough the 
production of extra-vesicular bodies.  
Our study underlines the importance of cross talk between blasts cells and bone cells, and the 
knowledge of the mechanism behind their interaction might help to anticipate the diagnosis 
including acute lymphocytic leukaemia in the differential diagnosis of musculoskeletal 
manifestations. Furthermore could be important to tailor the therapy in order to reduce the 
long-term squeal of the therapy side effects.  
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3. Materials and methods 
 
RANKL expression on leukaemia Bone Marrow blast cells 
 
Patients  
For B cell specific membrane RANKL expression patients PBMC and BM cells were 
obtained at the time of the diagnosis before therapy (68 B Common, 4 pre B, 7 pro B) and 
from healthy patients (11 stop therapy, and 4 maintenance) by density gradient centrifugation 
(Ficoll, Histopaque 1077, Sigma-Aldrich St. Louis, MO, USA). The local medical ethics 
committee approved this study.  
 
Flow cytometry analysis  
Flow cytometry analysis (FACS) was performed using specific antibodies (table 1), according 
to manufacturer’s instruction.  
 
Table 1: antibodies used in flow cytometry analysis. 
Cluster of differentiation Company Fluorophore Target cell 
CD7 Becton Dickinson FITC T cells 
CD15 Becton Dickinson FITC Monocytes precursor 
CD41 Becton Dickinson FITC Megakaryocytes, platelets 
CD14 Becton Dickinson PE Monocytes 
CD254 clone MIH24 eBioscience PE B cells, blasts, others 
CD45  Beckam coulter ECD Pan leucocytes 
CD33 Beckam coulter PC5 Myeloid cells 
CD3 Beckam coulter PC7 T cells 
CD19  Beckam coulter PC7 B cells, blasts 
CD61  Beckam coulter PC7 Megakaryocytes, platelets 
CD19  Becton Dickinson APC B cells, blasts  
 
A simplified antigen panel for leukaemia diagnosis includes the antigen CD19+, a leukemic 
blast marker, a pan leukocyte marker CD45, T specific antigen CD7 or CD3, a myeloid 
specific marker CD33, that allows for detection of granulocytes, monocytes and neutrophils 
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(see tables) and CD254. Fluorescence values for CD254 are given in median fluorescence 
intensity (MFI). 
 
Primary human osteoclast precursors isolation 
Mononuclear cells were isolated from human peripheral blood buffy coats from healthy 
donors by gradient centrifugation (Ficoll, Histopaque 1077, Sigma-Aldrich St. Louis, MO, 
USA). Subsequently, CD14+ monocytes were sorted using anti-CD14 coated magnetic beads 
Miltenyi Biotec GmbH 
Germany), according to manufacturer’s instruction. Purity of isolated population was assessed 
by FC (CD14 for monocytes, CD7 for T lymphocytes, CD19 for B lymphocytes, CD45 pan 
leucocyte, CD33 for myeloid lineage)  
Cells were re-suspended in α-MEM supplemented with 10% FBS, 100 U/ml penicillin and 
100 µg/ml streptomycin (Gibco), and subsequently used in co-colture experiments as 
described below. 
 
Co-culture experiment  
 
Co-colture into chamber slides  
3 x 10
5
 PBMC CD14+ cells/ml were seeded in each 4-Well Culture Slides (Falcon).  
The negative control were 3 x 10
5
 PBMC CD14 grown in maintenance medium supplemented 
with MCS-F (20ng/ml); the positive control were 3 x 10
5
 PBMC CD14 grown in 
osteoclastogenic medium (M-CSF 20 ng/ml, soluble recombinant RANKL 50 ng/ml). 
3 x 10
5
 PBMC CD14+ cells were grown in co-colture with 1 x 10
5 
B cell precursor leukaemia 
cell line (SEM ACC 546 from DSMZ) in maintenance medium. 
3 x 10
5
 PBMC CD14+ cells were grown in co-colture with 5 x 10
5
 CD19+ cells from BM of 
diagnosis or whole BM from healthy patients in maintenance medium. 
To assess RANKL specificity to induce multinucleation recombinant OPG was used to inhibit 
RANKL activity. The OPG was added both to the maintenance medium and to the 
osteoclastogenic medium, in controls and in wells with primary leukaemia cells and SEM 
cells.  
The culture medium was supplemented with MCS-F (25 ng/ml, Cell guidance system) and 
recombinant receptor activator nuclear factor ligand RANKL (50 ng/mL, Cell guidance 
system), OPG (50 ng/mL, Cell guidance system). SCF (Miltenyi), FLT3 (Miltenyi) for 
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primary leukemic cells (see table 2 for list of cytokine) and refreshed every 4 days, for a 
period of 12 days. 
 
Table 2: Cytokines used in co-colture experiments. 
Cytokines Company Working concentration 
MCS-F Cell guidance system  25 ng/mL 
RANKL Cell guidance system 50 ng/mL 
OPG Cell guidance system 25 ng/mL 
FLT3 Miltenyi 20 ng/mL 
SCF Miltenyi 5 ng/mL 
 
Multinucleation and TRAP assay  
Differentiated osteoclats were identified as tartarate–resistant acid phosphatase (TRAP-
positive) cells with three or more nuclei using Acid Phosphatase Leukocyte (TRAP) Kit 
(SIGMA), according to manufacturer’s instruction. Multinucleated cells were visualized and 
counted by light microscopy at Zeiss imager M1 equipped with Axiocam MRc5, Axiovision. 
A minimum of 200 cells was counted per each chamber and results are given as percentage.  
 
Bone plate Co-coltures  
Primary human osteoclast precursors were seeded in each well of the bone plate 
(OsteoAssay™ Plate, Lonza) at 30,000 precursors  
The negative control were 3 x 10
4
 PBMC CD14 grown in maintenance medium supplemented 
with MCS-F (20 ng/ml); the positive control were 3 x 10
4
 PBMC CD14 grown in 
osteoclastogenic medium (M-CSF 20 ng/ml, soluble recombinant RANKL 50 ng/ml). 
3 x 10
4
 PBMC CD14+ cells were grown in co-colture with 1 x 10
4 
B cell precursor leukaemia 
cell line in maintenance medium. 
3 x 10
4
 PBMC CD14+ cells were grown in co-colture with 3 x 10
4
 CD19+ cells from BM of 
diagnosis or whole BM from healthy patients in maintenance medium. 
To assess RANKL specificity to induce multinucleation recombinant OPG was used to inhibit 
RANKL activity. The OPG was added both to the maintenance medium and to the 
osteoclastogenic medium, in controls and in wells with primary leukaemia cells and SEM 
cells.  
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The culture medium was supplemented with MCS-F (25 ng/ml, Cell guidance system) and 
recombinant receptor activator nuclear factor ligand RANKL (50 ng/mL, Cell guidance 
system), OPG (50 ng/mL, Cell guidance system). SCF (Miltenyi), FLT3 (Miltenyi) for 
primary leukemic cells (see table for list of cytokine) for a period of 9 days. 
 
Resorption pits staining and enumeration 
CD14+ cells were plated onto bone plates (Lonza Osteo-assay) and treated with 20 ng/ml M-
CSF and 50 ng/ml RANKL for 7 days. The cells were completely removed with 10% 
hypochlorite and the bone plate was stained with toluidine blue 1%. Photographs of the 
resorption pits were obtained under a light microscope at 40× magnifications, with Opetech 
microscope equipped with DP200 camera and Deltapix software. Resorption pits number per 
each well was evaluated using ImageJ software. 
 
Gene expression profile 
RNA was extracted from bone marrow of patients, as well as from a series of healthy 
pediatric BM (HBM). RNA quality was assessed on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Waldbronn, Germany). Gene expression profile were obtained using GeneChip 
Human Genome U133 Plus 2.0 array (Affymetrix, Santa Clara, CS, USA) and normalized 
using RMA package from Bioconductor (www-r-project.org).(Bresolin et al., 2010).  
To study the involvement of B ALL in bone metabolism we make a list of genes involved in 
osteolysis pathway derived from the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway database. Unsupervised hierarchical clustering analysis using Euclidian distance and 
Ward methods were used to assess the different expression profiling of these genes in B-ALL 
patients and healthy donors. 
The Student t test was used for evaluate the differences between patients and HBM samples 
for selected genes. The Search Tool for the Retrieval of Interacting Genes (STRING) tool was 
utilized to build a protein-protein interaction (PPI) network and (DAVID Functional 
Annotation Bioinformatics Microarray Analysis was used to identify molecular networks) 
among genes resulted to be differently expressed. Table 3 shows the leukaemia subpopulation 
that has been used in this gene profile analysis. 
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Table 3: Gene expression profile ALL B subtype.  
Class  SubType  
1  ALL – mature B cells with t(8;14)  
2  ALL – prepreB, CALL with rearranged 11q23 (MLL)  
3  ALL – CALL, preB with t(9;22)  
4  ALL – all T subtypes  
5  ALL – CALL with t(12;21)  
6  ALL – t(1;19)  
7  ALL - hyperdiploid  
8  ALL – CALL, preB without t(9;22)  
18  Non-Leukaemia or normal BM  
 
Data analysis 
Statistical analysis was performed using Prism 4.02 (Graph Pad Software, San Diego, CA). 
Experiments were performed in duplicate or triplicate, and results were presented as mean of 
replicate experiments. Statistical significance was evaluated by the Mann Withney or 
unpaired Student t test where the latter was not possible. Differences were considered to be 
statistically significant at P values <. 05 and were indicated with asterisks (<. 05 *, < .001 **, 
< .0001 ***). 
 
 
Extracellular vesicles characterization 
 
Patients 
Peripheral Blood (PB) and Bone Marrow (BM) were collected after informed consent from 
healthy donors  (Stop Therapy, Maintenance) (6 PBs, 5 BMs) and patients at diagnosis of 
ALL B (20 B common, 3 pre B, 2 pro B, 1 relapse).  
 
Plasma Preparation for Extracellular vesicles analysis 
Cells, apoptotic bodies and eventually immune-complexes are removed from plasma by a 
combination of steps at the refrigerated centrifuge (Thermo scientific MicroCL21R) and 
filtration. Whole plasma is obtained by centrifuging at 1,500 g for 15’. Subsequent 
centrifugation for 15 minutes at 2,500 g (twice) depletes platelets in the plasma sample.  
The resulting supernatant is designated plasma platelet free (PFP). Plasma is finally filtered 
with 1,2 µm (FP 30/1 CA-S Whatman), to remove remaining debris.  
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Extracellular vesicles isolation  
EVs were isolated previously described (Ghosh et al., 2010) with minor modifications. PFP is 
centrifuged at 20,000 x g 60’ to obtain the pellet of extra cellular vesicles. The pellet is re-
suspended in a protein-free buffer phosphate-buffered saline (PBS) and stored at 4°C for 
further analysis. 
 
Extracellular vesicles Labelling 
For extra cellular vesicles labeling PFP is incubated with CellTrace™ CFSE 
(Carboxyfluorescein Succinimidyl ester) Cell Proliferation Kit Molecular probe (working 
concentration 3 µM) and stained for 20 minutes at room temperature with gentle agitation.  
After filtration PFP was centrifuged at 20,000 x g 60’ to obtain the pellet of extra cellular 
vesicles. The pellet is re-suspended in 20 µl phosphate-buffered saline (PBS) and labeled with 
1 µl of the following antibodies for flow cytometry analysis: CD254 PE, CD61 PC7, CD19 
APC (see table 1). Samples are incubated for 30’ at room temperature.  After incubation PBS 
cold is added up to 450-µl final volume ready for analysis.   
 
Extracellular vesicles Flow cytometry analysis 
Prior FC analysis 50 µl of 3 µm polystyrene beads (Polyscience.Inc Polybead® polystirene) 
were added to each sample and in the control tube at a final concentration of 200 beads /µl. 
These beads were used both as a relative size reference and as internal standard for measuring 
the acquired samples beads number. 
FS settings were adjusted using MegaMIx-Plus FSC beads (Biocytex) according to the 
manufacturer procedures. 
Samples were analyzed using MoFlow Beckman Coulter flow cytometer.  
The number of EVs was calculate by bead count assay as described before (Shet et al., 2003; 
Jayachandran et al., 2008; Jayachandran et al.,2013).   
 
Atomic Force Microscopy analysis of Extracellular vesicles   
A standard coverslip was cut into pieces 1”x0.5” (ca. 2.5 cm x 1.25 cm) using a diamond tip 
to fit into the AFM sample holder. The surface was cleaned first with pure deionized water 
(diH2O) and soap (rinse in diH2O) and then with acetone (rinse in EtOH). Both cleaning 
steps were ultrasound-assisted (80 kHz for 60 s) and the samples were dried in a N2 flow. Just 
before sample deposition, the samples were exposed to UV light for 60 s to further clean and 
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activate the surface. We used a CPII AFM from Digital Instruments (now Bruker) equipped 
with a V-shaped Si3N4 cantilever 0.6 µm thick of the sharp MicroLever (ML) series by Park 
Instruments, featuring a curvature radius of 2 nm. We chose in particular a ML06E cantilever 
(force constant 0.10 N/m, resonant frequency 38 kHz). Non-contact mode was also used to 
better visualize the morphology of isolated membrane bodies. AFM does not suffer from tip 
or sample degradation effects and is the eligible method for studying biological samples. 
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4. Results 
 
CD254 BM membrane expression in B ALL patients at diagnosis. 
As reported in literature leukaemia bone involvement is a clinical feature of patients before, 
during and after diagnosis of B ALL. RANKL (CD254) is the major and best-characterized 
player of the bone metabolism. It has been previously shown that it can be expressed in cells 
of B lineage and its expression is associated to bone erosion in several disease included 
rheumatoid arthritis or periodontitis (Kawai et al., 2006). For this reason we wanted to study 
if CD254 expression was a feature of leukemia patients’ blasts or B cells from healthy 
controls. In the attempt to address this point a flow cytometry approach was chosen. 
Membrane RANKL expression was analysed in the context of B ALL antigen panel.  
A typical analysis of leukaemia at diagnosis includes the antigen CD19+, a leukemic blast 
marker, a pan leucocyte marker CD45, T specific antigen CD7 or CD3, a myeloid specific 
marker CD33 (see table 1). We analyzed a total of 67 patients at diagnosis (56 common, 7 pro 
B, 4 pre B) and 22 controls (18 Stop therapy, 4 maintenance). Data are given as mean 
fluorescence intensity of CD254 gated on CD19+ cells. CD19/CD254 double positive cells of 
control patients where compared to CD19/CD254 double positive cells from patients at 
diagnosis (Figure 4 A). 
CD19+ cell of patients at diagnosis showed a heterogeneous but significantly higher level of 
membrane RANKL expression compared to control CD19+ bone marrow cells. The highest 
RANKL expression was associated to the Common B ALL types rather than to the other 
leukaemia subpopulations (pro and pre B diagnosis), in which RANKL expression was not 
significantly higher if compared to controls (data not shown).  
CD19+ PB and BM membrane RANKL expression was not different, showing a similar 
pattern of expression between the two compartments (7 Common diagnosis were analyzed) 
(Figure 4 B).  
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Figure 4 A and B: RANKL surface expression on BM cells from patients at diagnosis.  
67 Diagnosis (56 B ALL Common, 7 B ALL pro B, 4 pre B ALL) and 22 controls (18 Stop 
therapy, 4 maintenance) were investigated by flow cytometry using the RANKL monoclonal 
antibody (mAb) MIH24. Malignant and healthy B-lymphocytes cells were gated based on 
CD19. (A) Controls versus B ALL patients at diagnosis, including common, pre and pro B 
subtypes. (B) PB and BM CD254 expression of patients at diagnosis (7 Common). Statistical 
analysis was performed using the Mann–Whitney U test. Differences were considered to be 
statistically significant at P values <. 05 and were indicated with asterisks (<. 05 *, < .001 **, 
< .0001 ***). 
 
 
 
 
 
 
 
 
 
 
38 
 
RANKL expressing B leukaemia cell line SEM could induce differentiation of PBMC 
CD14+ into resorbing osteoclasts. 
Our previous data showed that RANKL membrane expression was significantly up regulated 
in patients at diagnosis compared to healthy controls.  
We thus ask if the expression of membrane RANKL was able to influence the cells involved 
in the bone metabolism, specifically the osteoclasts which carries on their membrane RANK, 
the receptor for the ligand CD254.  
In order to assess the ability of leukemic cells to influence osteoclasts precursor and their 
ability to differentiate into multinucleated cells and digest bones, we used SEM leukaemia 
cells line expressing RANKL, and we co cultured them with osteoclast precursor PBMC 
CD14+ cells on human bone slices for 7 days. After this period all the cells were removed and 
the bone slices were stained. In each co-colture experiment with SEM cell line we established 
as a negative control a well containing CD14+ cells only grown in maintenance media (MCS-
F). The positive control was represented by the CD14+ cells grown in presence of soluble 
recombinant RANKL as inducer of the full differentiation of the precursor into resorbing 
osteoclasts. SEM cell line expressing membrane RANKL were co cultured with CD14+ cells 
in maintenance medium (MCS-F only), and their ability to influence CD14+ towards 
differentiation into mature OCs was evaluated by number of resorption pits in each well. The 
RANKL specificity in inducing resorption by OCs was evaluated by using the soluble 
RANKL inhibitor, OPG. Pits were analyzed by light microscopy and the number of pits in 
each well was counted using Image J. Experiment were performed in duplicate. Figure 5 is a 
representative image of the resorption pits as visualized at the microscope with the 40X 
magnification. 
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Figure 5: Representative image of resorption assay. Resorption pits and lacunae formation 
on a human bone surfaces (96 well, Lonza Osteoassay).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
PBMC CD14+ co-colture with leukemic cell line SEM on bone plates. 
PBMC CD14+ monocytes were incubated in the presence of RANKL and MCS-F (as 
described in materials and methods) on a human bone surfaces for 7 days, or in presence of 
leukaemia cell line SEM expressing membrane RANKL (MFI 6). We observed pits formation 
with light microscopy (magnification 40×). Resorption pits/well were analyzed and counted 
using Image J software. 
PBMC CD14+ cells grown in presence of soluble recombinant RANKL showed a significant 
increase of resorption pits if compared to the untreated condition (Figure 6 A). The OPG 
treatment however was not significantly able to reduce the number of pits formed by CD14+ 
cells (Figure 6 B). CD14+ cells in co-colture with SEM cell line showed a higher number of 
resorption pits when compared to our untreated sample (Figure 6 C). CD14+ cells in co-
colture with SEM and treated with OPG showed a reduction of pits number in a significant 
manner. Figure 6 shows a single experiment performed in duplicate and showed that this 
leukemia cell line expressing RANKL (MFI 6), could indeed induce the resorption of the 
bone substrate, a resorption that seemed to be dependent on RANKL, as OPG significantly 
reduced the pits number (Figure 6 D). 
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Figure 6 A-D: PBMC CD14+ and SEM leukaemia cell line co-colture on Osteo-assay 
human bone plate (single experiment). After cells removal resorption pits were stained with 
toluidine blue and counted using Image J. (A) PBMC CD14+ cells grown in maintenance 
medium (MCS-F 20ng/ml, considered as negative control). These were compared to PBMC 
CD14+ cells grown in osteoclastogenic medium (MCS-F 20 ng/ml, soluble recombinant 
RANKL 50 ng/ml, considered as positive control), in order to assess the ability of PBMC 
CD14+ to differentiate in resorbing osteoclasts. (B) PBMC CD14+ cells grown in 
osteoclastogenic medium (MCS-F 20 ng/ml, soluble recombinant RANKL 50 ng/ml) were 
compared to PBMC CD14+ cells grown in osteoclastogenic medium (MCS-F 20 ng/ml, 
soluble recombinant RANKL 50 ng/ml) supplemented with recombinant OPG, to evaluate the 
osteoclastogenic dependence on RANKL cytokine. (C) PBMC CD14+ cells grown in 
maintenance medium (MCS-F 20ng/ml) were compared to PBMC CD14+ cells grown in co-
colture with SEM leukaemia cell line, expressing membrane RANKL at high level (MFI: 6). 
(D) PBMC CD14+ cells grown in co-colture with SEM leukaemia cell line were compared to 
PBMC CD14+ cells grown in co-colture with SEM leukaemia cell line supplemented with 
recombinant OPG, to assess the RANKL dependent ability to induce osteoclasts activity by 
resorption pits formation. Statistical analysis was performed using the Mann-Whitney U test. 
Differences were considered to be statistically significant at P values <. 05 and were indicated 
with asterisks (<. 05 *, < .001 **, < .0001 ***). 
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RANKL expressing SEM cells could induce differentiation of PBMC CD14+ into 
resorbing osteoclast. 
The first co-colture experiment with leukemia cell line showed the ability of these cells to 
induce bone resorption. We then performed two more experiments the results of which are 
summarized in figure 7.   
Figure 7 A-B shows the results of three different experiment performed co culturing SEM 
with CD14+ cells. SEM cell lines co-cultured with osteoclast precursor were able to increase 
in a significant manner the number of resorption pits (Figure 7 A), however the treatment with 
the RANKL inhibitor OPG did not significantly to reduce the number of resorption pits 
(Figure 6 B). The Figure 7 is the result of three different experiments, which were performed 
using SEM expressing different level of membrane RANKL. We can speculate that when the 
OPG is more abundant than the available RANKL, the soluble decoy receptor binds to other 
ligands expleting an anti apoptotic effect on mature OCs. Alternatively other pathways, 
different from RANKL, are involved. 
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Figure 7 A and B: PBMC CD14+ cells in co-colture with SEM leukaemia cell line in 
three different experiments performed on Osteo-assay human bone plate and pits 
number evaluation. (A) PBMC CD14+ cells grown in maintenance medium (MCS-F 
20ng/ml) were compared to PBMC CD14+ cells grown in co-colture with SEM leukaemia 
cell line, expressing membrane RANKL. (B) PBMC CD14+ cells grown in co-colture with 
SEM leukaemia cell line and PBMC CD14+ cells grown in co-colture with SEM leukaemia 
cell line supplemented with recombinant OPG, were compared to assess the RANKL 
dependent ability to induce resorption pits formation. Values were normalized to the positive 
control (resorption pits number in osteoclastogenic media). Statistical analysis was performed 
using the Unpaired T test. Differences were considered to be statistically significant at P 
values <. 05 and were indicated with asterisks (<. 05 *, < .001 **, < .0001 ***). 
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RANKL induced multinucleation of PBMC CD14+ cells in chamber slide colture system. 
We next wanted to test the ability of primary bone marrow leukemic cell to influence the 
osteoclast precursor PBMC CD14+ cells. In order to do that we performed co-colture 
experiment in chamber slides with the aim to understand if leukemic cells expressing 
membrane RANKL can induce fusion of single PBMC CD14+ cells into giant multinucleated 
cells.  
The figure 8 shows the detail of a mature multinucleate osteoclast after TRAP staining (more 
than 3 nuclei can be visualized). 
 
 
 
 
Figure 8: representative image of a multinucleated cell derived from PBMC CD14+ cells 
treated with recombinant RANKL. Detail adapted from figure 9 B. 
 
 
Figure 9 A-D is an example of TRAP staining of PBMC CD14+ osteoclast precursors grown 
in chamber slides. Recombinant human soluble RANKL in the colture the media induced 
multinucleation of PBMC CD14+ cells (Figure 9 C). OPG treatment completely abolished 
that fusion in to polykaryon of PBMC CD14+ cells (Figure 9 B and D).  
Figure 10 A-D shows an example BM cells from patients at diagnosis and control patient in 
cocolture with PBMC CD14+ cells. TRAP staining was used to evaluate the ability to induce 
multinucleation of PBMC CD14+ cells. The OPG treatment reduced the multinucleation both 
in the diagnosis and controls.  
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Figure 9 A-D: 20 x light microscopy representative images of PBMC CD14+ cultured in 
chamber slides. Tartarate-Resistant Acid Phosphatase (TRAP) was used to stain osteoclasts 
cells, which are TRAP resistant and multinucleated (with three or more nuclei). (A) Only 
PBMC CD14+ mononuclear cells were observed in unstimulated PBMC cultures (negative 
control). (B) Only mononuclear cells were observed in unstimulated PBMC cultures treated 
with OPG. (C) Multinucleated cells from PBMC stimulated with MCS-F and RANKL. (C) 
No multinucleated cells from PBMC stimulated with MCS-F and RANKL were upon OPG 
treatment.  
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Figure 10 A-D: 20 x light microscopy representative images of PBMC CD14+ co- 
cultured with whole BM from control patients and diagnosis patients in chamber slides. 
Tartarate-Resistant Acid Phosphatase (TRAP) was used to stain osteoclasts cells, which are 
TRAP resistant and multinucleated (with three or more nuclei). (A) Only few multinucleated 
cells were observed in PBMC CD14+ co cultures with whole BM from a control patient. (B) 
Only mononuclear cells were observed in PBMC CD14+ co cultures with whole BM from a 
control patient treated with OPG. (C) Multinucleated cells were observed in PBMC CD14+ co 
cultures with whole BM from a diagnosis patient. (D) Reduced number of multinucleated 
cells from PBMC CD14+ co cultures with whole BM from a diagnosis patient treated with 
OPG.  
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Chamber slide PBMC CD14+ co-colture with diagnosis and control patients.  
Figure 11 (A-H) represents the data from five different experiments performed using primary 
bone marrow cells from patients at diagnosis and controls. The membrane RANKL 
expression of diagnosis was variable (data not shown). For these experiments we considered 
all patients independently from their RANKL expression. In summary there were no 
significantly differences between our positive and negative controls (Figure 11 A). No 
differences between our negative control and our diagnosis (Figure 11 B). Similarly there 
were no differences between our diagnosis and controls (Figure 11 C). However the number 
of multinucleate cells in our positive control and in our diagnosis was increased compared to 
the negative. Furthermore the percentage of multinucleate cells in CD14+ co-colture with 
diagnosis was higher than the one with control patients (Figure 11 D). OPG treated co-colture 
percentage of multinucleate cells of diagnosis was significantly reduced compared to 
diagnosis not treated with the inhibitor (Figure 11 G).  
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Figure 11 (A-D): 5 different experiment of PBMC CD14+ co cultured with whole BM 
from control patients and diagnosis patients in chamber slides and showing different 
membrane RANKL expression. (A) PBMC CD14+ cells grown in maintenance medium 
(MCS-F 20ng/ml, considered as negative control). These were compared to PBMC CD14+ 
cells grown in osteoclastogenic medium (M-CSF 20 ng/ml, soluble recombinant RANKL 50 
ng/ml, considered as positive control). (B) PBMC CD14+ cells grown in maintenance 
medium (MCS-F 20ng/ml) were compared to PBMC CD14+ cells grown in co-colture with 
patients at diagnosis. (C) PBMC CD14+ cells grown in maintenance medium (MCS-F 
20ng/ml) were compared to PBMC CD14+ cells grown in co-colture with controls patients. 
(D) PBMC CD14+ cells grown in co-colture control patients were compared to PBMC 
CD14+ cells grown in co-colture with patients at diagnosis. A minimum of 200 cells was 
counted per each well. Statistical analysis was performed using the Mann-Whitney U test. 
Differences were considered to be statistically significant at P values <. 05 and were indicated 
with asterisks (<. 05 *, < .001 **, < .0001 ***). 
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Figure 11 (E-H): 5 different experiment of PBMC CD14+ co cultured with whole BM 
from control patients and diagnosis patients in chamber slides and showing different 
membrane RANKL expression. (E) PBMC CD14+ cells grown in osteoclastogenic medium 
were compared to PBMC CD14+ cells grown in osteoclastogenic medium in presence of 
OPG. (F) PBMC CD14+ cells grown in maintenance medium were compared to PBMC 
CD14+ cells grown in maintenance medium in presence of OPG. (G) PBMC CD14+ cells 
grown in co-colture with patients at diagnosis were compared to PBMC CD14+ cells grown 
in co-colture with patients at diagnosis in presence of OPG. (H) PBMC CD14+ cells grown in 
co-colture with control patients were compared to PBMC CD14+ cells grown in co-colture 
with control patients in presence of OPG. A minimum of 200 cells was counted per each well. 
Statistical analysis was performed using the Mann-Whitney U test. Differences were 
considered to be statistically significant at P values <. 05 and were indicated with asterisks (<. 
05 *, < .001 **, < .0001 ***). 
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Figure 11 (I-M): PBMCs CD14+ co cultured in chamber slides with whole BM from 
control patients and diagnosis patients showing high membrane RANKL expression (2 
different experiments). (I) PBMC CD14+ cells grown in maintenance medium were 
compared to PBMC CD14+ cells grown in co-colture with patients at diagnosis expressing 
high membrane RANKL. (L) PBMC CD14+ cells grown in co-colture with control patients 
were compared to PBMC CD14+ cells grown in co-colture with patients at diagnosis 
expressing high membrane RANKL. (M) PBMC CD14+ cells grown in in co-colture with 
patients at diagnosis expressing high membrane RANKL were compared to in co-colture with 
patients at diagnosis expressing high membrane RANKL in presence of OPG. A minimum of 
200 cells was counted per each well. Statistical analysis was performed using the Unpaired T 
test. Differences were considered to be statistically significant at P values <. 05 and were 
indicated with asterisks (<. 05 *, < .001 **, < .0001 ***). 
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High RANKL membrane expression diagnosis blast cells induced multinucleation of 
PBMC CD14+ cells in chamber slides co-colture system. 
The positive correlation between higher membrane RANKL expression and the percentage of 
multinucleate cells is shown in figure 12 A, which includes all patients involved in this 
experiment, both controls and diagnosis. 
High and low RANKL expressing BM cells from diagnosis were compared. We found there 
was a significant increase in the percentage of multinucleate cells in high RANKL expressing 
patients (Figure 12 B).  
 
 
 
 
Figure 12 A and B: (A) Correlation MFI CD25/CD19 and multinucleation in patients 
grown in chamber slide co-coltures (7 Stop therapies, 5 diagnoses). The MFI of CD254 
gated on CD19+ cells significantly correlates with the number of multinucleate cells 
(Spearman positive correlation). (B) Multinucleate cells generated from PBMC CD14+ co-
colture with BM of patients at diagnosis (chambers co-colture) and grouped according to their 
RANKL expression. Statistical analysis was performed using the Mann-Whitney U test. 
Differences were considered to be statistically significant at P values <. 05 and were indicated 
with asterisks (<. 05 *, < .001 **, < .0001 ***). 
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RANKL expressing blasts cells can induced multinucleation of CD14+ precursor in bone 
plates. 
In order to confirm our analysis of B ALL cells ability to influence PBMC CD14+ cell 
towards osteoclast differentiation we performed co-colture experiment using bone slices 
substrates. 
For this purpose we used bone marrow from patients high membrane RANKL expression 
(MFI between 2,5 and 7) and from a control patient (3 different experiments made in triplicate 
or duplicate). 
Figure 13 A-H summaries the results. The percentage of multinucleate cells in the untreated 
co-colture was significantly lower compared to RANKL stimulated cells. The untreated 
PBMC CD14+ cells showed a significant lower percentage of multinucleate cells compared to 
diagnosis patients. Co-colture with diagnosis showed significantly higher number of 
multinucleate cells compared to controls patients. The OPG treated co-colture showed a 
reduction of multinucleate cells in all cases analyzed but none of them were significantly 
affected by the OPG treatment. Once again we saw that the OPG inhibitor of RANKL does 
not always work on arresting PBMC CD14+ differentiation towards osteoclast lineage. 
Further analyses are required.  
Of note, for these experiment we used 2 BMs from patients with known bone involvement, 
one of them was suffering for extensive bone lesions at the time of the therapy. This patients 
was showing the highest RANKL membrane expression among the one here analyzed. 
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Figure 13 (A-D): PBMC CD14+ co cultured in bone plates with whole BM from control 
patients and diagnosis patients showing membrane RANKL expression (3 different 
experiments). (A) PBMC CD14+ cells grown in maintenance medium (MCS-F 20ng/ml, 
considered as negative control). These were compared to PBMC CD14+ cells grown in 
osteoclastogenic medium (M-CSF 20 ng/ml, soluble recombinant RANKL 50 ng/ml, 
considered as positive control). (B) PBMC CD14+ cells grown in maintenance medium were 
compared to PBMC CD14+ grown in co-colture with patients at diagnosis with different 
RANKL expression (see table). (C) PBMC CD14+ cells grown in maintenance medium were 
compared to PBMC CD14+ cells grown in co-colture with control patients. (D) PBMC 
CD14+ grown in co-colture with patients at diagnosis with different RANKL expression were 
compared to PBMC CD14+ cells grown in co-colture with control patients. Statistical 
analysis was performed using the Mann-Whitney U test. Differences were considered to be 
statistically significant at P values <. 05 and were indicated with asterisks (<. 05 *, < .001 **, 
< .0001 ***). 
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Figure 13 (E-H): PBMC CD14+ co cultured on bone plates with whole BM from control 
patients and diagnosis patients showing membrane RANKL expression (3 different 
experiments). (E) PBMC CD14+ cells grown in osteoclastogenic medium were compared to 
PBMC CD14+ cells grown in osteoclastogenic medium in presence of OPG. (F) PBMC 
CD14+ grown in maintenance medium were compared to PBMC CD14+ grown in 
maintenance medium in presence of OPG. (F) PBMC CD14+ cells grown in osteoclastogenic 
medium (M-CSF 20 ng/ml, soluble recombinant RANKL 50 ng/ml were compared to PBMC 
CD14+ cells grown in co-colture with patients at diagnosis expressing RANKL. (G) PBMC 
CD14+ grown in co-colture with control patients were compared to PBMC CD14+ cells 
grown in co-colture with patients at diagnosis expressing RANKL. (H) PBMC CD14+ grown 
in co-colture with control patients were compared to PBMC CD14+ grown in co-colture with 
control patients and treated with OPG. Statistical analysis was performed using the Mann-
Whitney U test. Differences were considered to be statistically significant at P values <. 05 
and were indicated with asterisks (<. 05 *, < .001 **, < .0001 ***). 
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Gene expression profile of B ALL patients. 
 
Down regulation of genes involved in osteoclastogenesis.  
With the attempt to understand if blast cells behave as stromal like cells, supporting OCs as 
seen from the above results, or as OCs precursor themselves, we performed a gene profile 
analysis.  RANKL can be involved in three different pathways, as a ligand in the in B cell 
lymphoiesis, and in osteobalstogenesis pathway or can be involved through RANK receptor 
in the osteocalstogeneisis.  
We analyzed the osteoclastogenic and osteoblastogenic and the B cell differentiation pathway 
pathways derived from the Kyoto Encyclopedia of Genes and Genomes (KEGG). 
Surprisingly we found that there were no differences between BM of control patient and 
diagnosis of B ALL concerning the osteogenic and B lymphopoiesis pathways (data not 
shown), however there were for the osteoclastogenic one. We found that control patients and 
diagnosis clustered and that in the B ALL cohort here analyzed the osteoclastogenic pathway 
was down regulated. Figure 14 A shows the heat map and in the red boxes are genes 
differentially expressed. As shown by the Search Tool for the Retrieval of Interacting Genes 
(STRING) analysis those genes are interacting partner of this pathway (Figure 14 B).  
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Figure 14 A and B: Osteoclastogenesis KEGG derived pathway and interacting proteins. 
(A) Heat map of genes involved in osteolysis pathway derived from the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway database. Unsupervised hierarchical clustering 
analysis using Euclidian distance and Ward methods were used to assess the different 
expression profiling of these genes in B-ALL patients and healthy donors. Genes 
differentially expressed are highlighted in red. Differences were considered to be statistically 
significant at P values <. 05 and were indicated with asterisks (<. 05 *, < .001 **, < .0001 
***). 
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Figure 14 (B): Search Tool for the Retrieval of Interacting Genes (STRING). Protein-
protein interaction of genes differentially expressed according to gene expression profile and 
built using the STRING. 
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Genes involved in osteoclasts specific metabolism and in osteopetrosis disease.  
In order to understand if the down regulation was associated to a defect of osteoclast like 
genes and not to genes that could also be involved in B cell differentiation (as DAP12 and 
SYK), we performed GEP analysis on a group of genes that are involved in osteoclasts 
maturation differentiation and eventually in bone disease associated to not functional 
osteoclasts (Coudert et al., 2014), Figure 15. 
Interestingly we found a strong separation in clusters of control patients versus diagnosis. 
This suggests that the alteration of osteoclast specific genes have a role in B ALL etiology 
that requires further analysis, as it will be discussed in the next sections. 
 
 
Figure 15: Heat map of genes with known osteoclastsic functions and involved in 
osteopetrosis. Unsupervised hierarchical clustering analysis using Euclidian distance and 
Ward methods were used to assess the different expression profiling of these genes in B-ALL 
patients and healthy donors. Genes differentially expressed are highlighted in red. Differences 
were considered to be statistically significant at P values <. 05 and were indicated with 
asterisks (<. 05 *, < .001 **, < .0001 ***). 
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Plasma EVs from B ALL patients at diagnosis and controls.  
 
Flow cytometry characterization of Extracelular Vescicles membrane antigens.  
Our co-colture experiment results showed that B ALL blats cells with high membrane 
RANKL expression could influence the OCs precursor through a pro osteoclastic phenotype. 
We could not address if the effects mediated by RANKL was direct, in contact – contact 
mode, or indirect by release of soluble factors.  
Here we studied the cell-cell communication through EVs, and we characterized EVs from 
peripheral blood plasma of patients at diagnosis, and from peripheral blood and bone marrow 
plasma of control patients.  
 We isolated EVs from the peripheral blood (PB) plasma of untreated B ALL patients at 
diagnosis as well as healthy subjects (Stop therapy and maintenance). The isolation protocol 
was adapted from a previous work on chronic lymphocytic leukaemia (CLL) (Ghosh et al., 
2010), with minor modifications. In order to analyze EVs at the flow cytometry, we used the 
cytoplasmic dye CFSE that allows the selection of intact membrane bodies containing 
cytoplasm. Our EVs gate was also defined on the basis of forward/side scatter with the use of 
3 μm beads and were considered positive events the ones falling in the in the range of 300-
800 nm. This allowed us to exclude the eventual residual cells or platelets that could have left 
behind the plasma platelet free preparation (Figure 16 A and B). 
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Figure 16 A and B: (A) Representative flow cytometry dot plots of EVs physical 
properties. (A) EVs isolated from PB of a patient at diagnosis and characterized 
morphologically. EVs gate according to Side Scatter (SSC) and Forward Scatter (FSC), and 
polystyrene beads used for size definition (3 µm). The scattergram shows the events detected 
in the gate from a sample re-suspended in PBS and containing beads. Beads number is 
standard and the same per each test tube and serve to number EVs using the bead count assay. 
(B) Identification of CFSE labeled EVs only, in the FITC- fluorescence channel.  
 
 
 
 
 
 
61 
 
Atomic Force Microscope: size overview 
Atomic force microscopy showed that the EVs isolated are heterogeneous population with the 
majority ranging in size from 300 nm to 500 nm.  
Figure 17 (A-C) are representative images taken with the AFM in both contact (A-B) and 
non-contact mode (C). Analysis were performed on EVs form PB and BM of controls and 
patients at diagnosis. The first two figures were taken on a BM plasma sample of EVs from 
diagnosis patients in contact mode. Figure A shows a typical population as seen in AFM. 
Figure B shows the measure of the isolated EVs. Figure 17 C representative image in contact 
mode of the EVs shape. AFM microscopy was performed to confirm that we are isolating 
membrane vesicles rather than cell debris or immune-complexes. The size and the shape 
matched with our expectations. 
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Figure 17 A - C: AFM representative imaging of isolated EVs. (A) AFM imaging in 20 
µm x 20 µm scan. All measurements were performed in air and in contact mode with constant 
force. Image resolution was 256 pixels x 256 pixels, the set point force was 5 pN and the scan 
rate was 1 Hz.  
(B) AFM imaging measured profiles taken on 20µmx20µm scans. Profiles are indicative of 
the EVs height and width. The representative range of our isolated population is between 100 
nm and 300 nm. 
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Figure 17: (C) AFM imaging in non-contact mode: representative image of 10umx8um 
scan on EVs, taken in. non-contact mode. Only shape was considered in this picture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
EVs surface antigen characterization by flow cytometry. 
In the normal plasma the majority of EVs originates from platelets (80%), and only about 
10% are represented by leukocytes EVs (George et al., 1982; Caby et al., 2005). In chronic 
lymphocytic leukaemia most the EVs are produced by CD19+ blasts (Ghosh et al., 2010).    
We used CD19 as marker for EVs derived from blasts and normal B cell, CD61 marker for 
platelet/megakaryocyte and CD254 as bone specific marker (Figure 18).  
We considered the CFSE positive events calculated as described in material and methods, as 
the total population irrespectively of the surface markers. We found that significant greater 
levels of EVs were present in the plasma of our control patients compared to leukemic 
patients (P<0.001). The analysis of the CDs markers was performed gating on CFSE+ EVs. 
CD61 was highly expressed in control patients, and was significantly lowered in leukemic 
patients at diagnosis (P<0001), as described before. Interestingly CD254 EVs were present in 
the control plasma and significantly increased compared to diagnosis. In the controls the 
numbers suggest that most of the CD61 are also CD254 positive. Other cell populations can 
produce CD254+ EVs, but our antigen panel does not allow knowing which ones. Due to the 
heterogeneous CD19 expression in our controls, there was no difference with the diagnosis 
but the trend is negative, with low EVs CD19+ at diagnosis compared to healthy subjects. In 
control patients’ most part of CD19+ EVs population is also CD254 positive. At diagnosis 
there is a minor population CD19+ CD254 double positive. This confirmed that blasts cells 
might not be the major source of EVs in the plasma of patients at diagnosis, and it is 
consistent with the observation of the BM cells, as it is described in the next section.  
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Figure 18 A-F: Characterization of CDs on PB plasma EVs. (A) Cytoplasmic dye CFSE 
was used to characterize the overall number of EVs in control patients (6 stop therapy) versus 
diagnosis patients (20 B ALL Common, 3 pre B ALL, 2 pro B ALL, 1 relapse). (B) CD254 
bone marker expression was evaluated in EVs CFSE+ from control patients and compared to 
diagnosis patients. (C) CD61 megakaryocytes/platelets marker expression was evaluated in 
EVs CFSE+ from control patients and compared to diagnosis patients. (D) CD19 leukaemia 
blasts and B-lymphocytes expression was evaluated in EVs CFSE+ from control patients and 
compared to diagnosis patients. (E-F) Double positive CD254/CD61 and CD254/CD19 EVs 
population analysis: controls versus diagnosis patients. Statistical analysis was performed 
using the Mann–Whitney U test. Differences were considered to be statistically significant at 
P values <. 05 and were indicated with asterisks (<. 05 *, < .001 **, < .0001 ***). 
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Bone Marrow and peripheral blood compartments: EVs in control patients. 
The same analysis of the PB markers described before was performed on plasma from bone 
marrow (BM) in control patients only (Figure 19). Similarly to the PB, the EVs from BM 
shows that the most represented populations are CD254+ and CD61+ positives. Moreover the 
overall number of EVs in BM is significantly higher compared to PB. The numbers suggests 
that the EVs observed in the PB derive from bone marrow parental cells.  
 
 
 
Figure 19 (A-F): Characterization of CDs on PB and BM plasma EVs from control 
patients. (A) Cytoplasmic dye CFSE was used to characterize the overall number of EVs in 
control patients (6 PBs, 5 BMs). EVs number/ml were calculated as described before. CFSE + 
EVs were then characterized for different CDs. (B) CD254 bone marker expression was 
evaluated in EVs CFSE+. (C) CD61 megakaryocytes/platelets marker expression was 
evaluated in EVs CFSE+ from control patients. (D) CD19 leukaemia blasts and B-
lymphocytes expression was evaluated in EVs CFSE+ from control patients. (E-F) Double 
positive CD254/CD61 and CD254/CD19 EVs population analysis in controls PB versus BM. 
Statistical analysis was performed using the Mann–Whitney U test. Differences were 
considered to be statistically significant at P values <. 05 and were indicated with asterisks (<. 
05 *, < .001 **, < .0001 ***). 
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Bone Marrow compartment: CD254 and CD61 cell membrane expression in control and 
patients at diagnosis. 
PB EVs analysis of control and diagnosis patients showed the presence of a double positive 
CD254/CD61 population and that in control patients the overall production of the membrane 
bodies is greater compared to patients at diagnosis. 
We wanted to understand if the situation described in the PB through EVs was representative 
of the bone marrow. We asked how CD254 marker is associated to CD61 antigens in healthy 
patients. For this purpose we performed flow cytometry analysis on bone marrow cells of 
controls and diagnosis (Figure 20). We found that CD61+ cells also express CD254 in the BM 
of the control patients. The number of CD61/CD254 in patients at diagnosis is lowered 
compared to controls because of the overwhelming CD19+ blast population. The presence of 
CD61/CD254 double positive cells suggests that those could be the source of EVs present in 
the PB and at major extent in BM.  
 
 
 
Figure 20 A and B: Megakaryocytes/plateles markers in BM cells from control patients 
and B ALL diagnosis patients. (A) Flow cytometry analysis of CD61 and (B) CD61/CD254 
expression on freshly isolated BMs cells from controls (5 stop therapy, 1 maintenance) and 
diagnosis (6 ALL B). Results are given as percentage. Statistical analysis was performed 
using the Mann–Whitney U test. Differences were considered to be statistically significant at 
P values <. 05 and were indicated with asterisks (<. 05 *, < .001 **, < .0001 ***). 
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5. Discussions 
 
RANKL membrane expression in B ALL blast cells. 
The importance of CD254 in leukaemia is represented by its pivotal role in bone metabolism. 
Leukaemia disease is often associated with musculoskeletal involvement, a condition that 
accompanies the patients from the diagnosis to the follow up. CD254 can be expressed by the 
lymphoid lineage by activated T cells and this is linked to their ability to positively stimulate 
the resorption activity of osteoclasts. Furthermore it has been shown that activated CD19+ B 
cells, similarly to activate T cells are involved in osteoclast activation and bone degradation in 
periodontal disease, rheumatoid arthritis and in B cell lymphoma neoplasm (Kong et al., 
1999; Kawai et al., 2006; Horowitz, 2010). Thus in literature it is well described that 
deregulation in the RANKL expression and pathways activated by this ligand can have a pro 
osteoclastic effect.  
Initially our flow cytometry analysis reveled that blasts cells from B ALL patients at 
diagnosis had a significantly increased RANKL membrane expression compared to control 
patients. Membrane RANKL expression in patients at diagnosis was heterogeneous (Figure 
4). Pre B and pro B cells did not showed the same RANKL expression as common B ALL 
(data not shown). RANKL membrane expression in leukemic cells has been reported on AML 
primary blasts (Schmiedel et al., 2012) but B ALL expression is a novelty. This first data 
suggest that RANKL expressed on blasts cells could also have a functional role in acute 
lymphocytic leukaemia.  
We thus decided to study how CD19+ blast cells can influence the bone environments, and 
specifically the bone digesting osteoclasts. To do this we performed 2D co-colture experiment 
on bone plates using a leukaemia cell line SEM, expressing membrane RANKL. We tested 
the ability of leukaemia cell line to induce differentiation of PBMC CD14+ osteoclasts 
precursor into resorbing cells, by analyzing number of pits on the bone substrate (Figures 6 
and 7). SEM cells were able to induce differentiation of the PBMC CD14+ in bone degrading 
osteoclast (see Figures 6 and 7). However the only known RANKL inhibitor OPG was not 
able to significantly reduce the bone digestion by OCs, both in SEM co-colture and in OPG 
treated positive control (Figure 7).  
We then analyzed the ability of primary BM cells from diagnosis and from control patients to 
influence the PBMC CD14+ differentiation towards the mature osteoclast. We choose the 
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TRAP staining assay and we studied the first step of osteoclasts differentiation, the ability to 
fuse to generate multinucleate cells (with more then 3 nuclei), see Figure 10 and 11.  
To investigate this aspect we performed co-colture in chamber slides using patients at 
diagnosis showing different RANKL expression and controls (Figure 11 A-H).  
Only patients at diagnosis with high RANKL expression were able to induce multi-nucleation 
of PBMC CD14+ in a significant manner (Figure 11 I-M). Moreover the treatment with OPG 
significantly reduced the ability of RANKL expressing cells to induce fusion into giant OCs 
(Figure 11 E-H). 
Same experiment was performed on bone plates, which seemed a more physiological 
substrate for OC precursors adhesion and differentiation. This set of experiments showed that 
BMs from patients at diagnosis expressing RANKL could induce osteoclasts precursor to fuse 
to form multinucleate cells (Figure 13 A-D). However the OPG treatment was not efficient 
blocking the RANKL activity (Figure 13 E-H).   
The OPG is the only known inhibitor for RANKL. The fact that the OPG is not always 
efficient in blocking multinucleation might also suggest that other mechanisms other then 
RANKL are involved, and this aspect need to be further investigated. However OPG can bind 
to another receptor on OCs, which is the TNF-related apoptosis inducing ligand (TRAIL). 
This is an apoptotic receptor, which may have the opposite effect in condition where RANKL 
is not sufficient to interact with the OPG and be sequestered it. OPG concentration in the co-
colture system is probably more than the RANKL produced by blasts. Nonetheless there is a 
positive correlation between the RANKL membrane expression and the number of 
multinucleate cells, as shown in figure 14 A. Patients at diagnosis showing high RANKL 
expression (MFI above 2,5 to 7) had an increased number of multinucleate cells when 
compared with controls and diagnosis patients with low RANKL expression (MFI below 2) 
(Figure 14 B). Whit these data we cannot exclude that only specific CD14+ are responsive to 
CD254, and further analysis are required. The OPG anti-apoptotic effect has been shown for 
committed OCs (Chamoux et al., 2008), thus it is possible that CD254+ blasts cells exert their 
osteoclastogenic effects on more immature osteoclasts. Other molecules, already in use in 
clinic, could offer an interesting alternative to recombinant OPG, (Denosumab). It could be 
tested in this system to assess the ability to inhibit high bone degradation in patients with high 
RANKL expression. 
These finding support the concept that there is an important cross talk between B cells and the 
microenvironment. Until now the attention has been mainly focused on stromal osteoblastic 
cells, rather then on bone resorbing cells. However the importance of osteoclasts in the 
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hematopoietic compartment it is well known, above all from osteopetrotic mice models. 
Osteoclasts are physically responsible for the niche formation, and hematopoietic cells 
egression. Furthermore feedback signals from OCs are necessary for osteoblastic cells 
activity, stimulating their activity. An example is the osteoporosis treatment where anti-
resorptive drugs used to reduce the bone erosion leads to a concomitant reduced bone 
formation (Charles and Aliprantis 2014). In leukaemia we see that a plethora of different bone 
alterations come at presentation, during the therapy and persist as a long-term sequel after 
treatment. In this study we analyzed RANKL membrane expression on patients with known 
bone involvement. Two of them were also used in co-colture experiment, and we clearly saw 
that in those cases the multinucleation was associated with high RANKL MFI. Our data 
support the idea that blasts cells can expresses RANKL on their membrane and that this can 
influence osteoclast precursors to multinucleate. The immune system is functionally and 
physically related to bone. Members if the TNF ligand/receptor superfamily and several 
cytokines are essentials for the function and normal development of both systems (Manabe 
2001; Monsour et al., 2011; Horowitz et al., 2005). Moreover immune and bone cells have 
common progenitors. Commitment to the B cell lineage depends on Pax5, and Pax5 deficient 
mice pro B cells can differentiate in to osteoclasts as well in absence of IL7 and estrogen 
(Blin Wakkach et al., 2006; Miyaura et al., 1997).    
RANKL deficient mice showed a severe osteopetrosis, because of the complete lack of 
osteoclasts. These mice also showed a disruption of the B cells differentiation, were transition 
from pro B to pre B stage is compromised and this defect is a B cell intrinsic phenomenon and 
not to due to the microenvironment. B cell differentiation from hematopoietic stem cells to 
immature B cells in the bone marrow is achieved after successive rearrangement of the gene 
segments of the heavy IgH and light IgL chain loci (Tonegawa et al., 1983). When a 
functional rearrangement occurs at the pro B to pre B stage the cells will express the pre B 
cell receptor (pre BCR) (Karasuyama et al., 1990; Melchers et al., 1993). When pre BCR is 
expressed on pro B cells surface those can expand in the presence of low IL7 concentration. 
IL7 is produced by stromal cells and is required both for lymphopoiesis and 
osteoclastogenesis, providing a nurturing microenvironment for their progenitors cells. Also 
IL7 deficient mice show osteopetrosis and suppression of early B lymphopoiesis. In contrast 
IL7 overexpressing mice or IL7 treated mice shows and increase in B lymphopoiesis and bone 
loss (Stoddart et al., 2000; Miyaura et al., 1997).  
Kato showed that RANKL/TRANCE membrane expression in mice is stage specific regulated 
Kato et al., 2003). Pre B cells, which are proliferative, express RANKL and can differentiate 
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further to the immature cells with removal of IL7. Thus RANKL transcription depends on 
IL7, and it is limited to proliferating cells, such as Abelson virus transformed pre B cell lines 
or IL7 dependent pre B cells. RANKL induce cells to proliferate after an inhibition of G1 
arrest. The physical proliferation of pre B cells increases the differentiation rate. 
We did not see clear association between high RANKL expression and the cell cycle, even 
though we suspect that RANKL expression on blasts cells might be associated to a more 
differentiated blats sub population. When dividing diagnosis and controls by their CD254 
MFI into quartiles (data not shown), we saw that the patients with known bone lesions are in 
the III and IV quartile. The third and fourth quartiles were also associated to the highest 
number of aneuploidy cell cycle, even though this did not correlate with DNA index, or S 
phase. Cell cycle analysis was performed on the whole bone marrow blast population, but the 
patients we analyzed showed heterogeneity for the RANKL expression as described before. 
During our flow cytometry analysis we often observed that CD254/CD19 double positive 
cells were not always representative of the whole blasts population, as if within the CD19+ 
gate there were two different sub groups. Similarly to the results described by Kato, among 
blast population double positive CD19+CD254+ cells could represent a more differentiated 
population of leukemic cells.  
Further cell cycle analysis are required in order to understand RANKL membrane expression 
role in cell cycle; DNA index or S phase length might not be fully informative of other phases 
as the spindle formation and checkpoint activity. Our patients’ data need to be implemented 
and the RANKL expression needs to be studied for correlation with possible prognostic 
factors. The fact that blasts can express at high level RANKL and the possibility that this can 
induce bone resorption should be taken into account.  Recently a Danish study has focused on 
the delay of the diagnosis of B ALL due to atypical presentations. They reported a study of 
100 children which symptoms, signs and laboratory findings at the time of the presentation. 
They found that among children with pre B ALL, musculoskeletal pain is reported by more 
than half, and that 10% manifest joint or bone lesion resembling arthritis and osteomyelitis. 
Children with skeletal lesions have a longer diagnostic interval with slower disease 
progression and associated with good prognosis, unless diagnosis is much delayed (Heinrich 
et al., 1994; Muller et al., 1998). They suggested the blast crisis when the full-blown bone 
marrow occurs is a late occurrence of disease progression. Today the efficacy of treatment has 
greatly improved and knowing more about RANKL function might help to anticipate and 
tailor therapy, or could be used for the stratification of the patients. Whether the 
multinucleation induced on osteoclasts precursor by RANKL expressing blasts can end with 
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full osteoclast activation has to yet to be addressed, but our results are in agreement with work 
made by other groups and with clinical data. 
Many other points need to be addressed in order to consider this bone marker in leukaemia 
and RANKL expression need to be studied in a more complex of interaction as it will be 
described in the next section.  
 
 
Gene Expression Profile analysis in B ALL patients at diagnosis and controls.  
Our results strongly suggested that high membrane RANKL expression in B ALL blasts could 
induce multinucleation of osteoclasts precursor (Figure 11 and 13). The 2D co-colture system 
was informative of the effects that leukaemia cells had on CD14+ OCs precursor. However 
we do not know from these data if leukemic cells do serve as osteoclasts precursor itself.  
We performed gene profile analysis in order to gain information about the possibility that 
leukemic blats and RANKL expression could influence the bone metabolism through the 
three major pathway in which RANKL is involved: osteoclastogenic, osteoblastogenic and B 
cell differentiation as derived from KEGG. Our cohort includes all the B ALL classes as 
shown in table 3 in material and methods. 
Manabe (Manabe et al., 2001) reported that in mice B lymphoid lineage cells expressed 
RANKL and had the ability to support osteoclast differentiation. Furthermore a subset of 
normal bone marrow cells that expresses markers of B lymphoid lineage cells in early 
developmental stages can serve as osteoclast progenitors and are able to differentiate in to 
resorbing osteoclasts in vitro (Manabe et al., 2001; Blin-Wakkach et al., 2006).  
With this in mind we performed GEP analysis and found that among the pathways analyzed 
only the osteoclastogenic pathway was altered in our B ALL cohort (Figure 14 A). 
Among genes differentially expressed there are interacting partner as shown in figure 14 B. 
Of these genes DAP12 and CD300d have been directly implicated in B cell differentiation.  
DAP12 is the product of the gene TYROBP. Is an immune receptor tyrosine-based activation 
motif-bearing adapter protein. It represents a co-stimulatory pathway in the RANKL cascade. 
Mutations of this gene are responsible of a recessive genetic disorder named Nasu-Hakola. 
Upon ligand binding DAP12 trigger intracellular activation via the ITAM motif, reaching the 
SYK family kinases and inducing their phosphorylation.  
Yokomizo (Yokomizo et al., 2011) described DAP12 and its role in human B cells. They 
showed that DAP12 together with CD300d negatively regulates B cell mediated adaptive 
immune responses and suppress their B cell receptor (BCR) mediated proliferation. Absence 
74 
 
of DAP12 in human B cells made them hyper responsive to BCR mediates stimulation also 
increasing their proliferation rate.   
SYK regulates several signaling events in lymphoid cells (Uckun et al., 2010). After its 
activation SYK phosphorylates several signaling molecules triggering a cascade of signal 
transduction that affect activation, proliferation ad survival (Uckun et al., 2014). SYK it is a 
part of the pre BCR signaling in B cell precursors as well as BCR signaling in mature B-
lymphocytes and it plays an important role in early specification and maturation events during 
B cell ontogeny (Uckun et al., 2014). SYK is also involved in normal osteoclast function in 
vivo and in vitro. Osteocalsts defective for SYK showed no defect in their differentiation but 
were unable to re organize their cytoskeleton and as such their ability to resorb bone (Zou et 
al., 2007). DAP12 and mature B-lymphocytes act synergistically to maintain bone mass under 
physiological conditions. When osteoclasts function is compromised as in Dap12 mutant mice 
(KΔ75, osteopetrotics) they can function as accessory cells to regulate osteoclasts function 
(Anginot et al., 2007). On the other side mice overexpressing DAP12 have an osteopenic 
bone phenotype due to an increased number of osteoclasts on the surface of trabecular and 
cortical bone. Again the increased osteoclastogenesis results in an impaired hematopoiesis 
with concomitant arrest of B cell differentiation arrest at the pre-proB/pre B stage (Despars et 
al., 2013).  
Thus some of the genes are directly involved in B cell maturation whereas others have a more 
important role in the functional differentiation of osteoclasts, mainly in their cytoskeleton 
reorganization rather than in their differentiation.  
With the attempt to better understand if the osteoclastogenic involvement of B ALL 
leukaemia cells was due to an impaired B cell differentiation or rather to the possibility that 
blasts cells could be a defective or dormant osteoclast precursor we analyzed some of the gens 
that are specifically involved in human osteopetrosis (Lange et al., 2006; Coudert et al., 2014) 
(Figure 15). 
Of the gene analyzed we found that were differentially expressed genes that are known or for 
their role in osteoclasts functionality as OSTM1, SERPINE2, and WARS. 
OSTM1 and CLC-7 both co localize in the late endosomes and lysosomes of various tissues 
included the ruffled border of resorbing osteoclasts. OSTM1 and CLC-7 form a molecular 
complex.  Together they are required for acidification of the resorption lacunae (Lange et al., 
2006).  
SERPINE2 it is involved in the removal of non-collagenous proteins that are present in the 
non-mineralized bone matrix, but it is not required for their differentiation or for the 
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resorption on bone matrix (Daci et al., 1999). WARS catalyze the aminoacylation of tRNA 
(Trp) with tryptophan for protein synthesis, and is involved in osteoclasts differentiation 
(Chabbi Achengli et al., 2012).  
To data this is the first study performed on B ALL leukaemia blast cells that focus on the 
interaction with bone degrading cells. Importantly here we highlighted the possibility that 
leukemia B cells and osteoclast share more than common transcription factors at early 
differentiation stages, but their respective development is closely linked.  
We need to understand if RANKL expressing primary blasts population can induce bone 
resorption and lacunae formation. If blast cells, which do not express RANKL, can be 
differentiated into osteoclasts upon RANKL and MCS-F stimulation.  
The GEP analysis unveiled the possibility that beyond a direct effect on osteoclast mediated 
by RANKL expressing blast, there are shared pathways between leukemia and osteoclasts 
alteration of which might contribute to the disease progression. Our next focus will be on the 
RANKL expression on pro B and pre B cells and the effects the down regulation or 
overexpression can induce in these cells. The description of RANKL membrane expression 
on blasts represents a small piece of a puzzle of interactions within the bone marrow.  
Notably in this context of cell-to-cell communication the shedding of extra cellular vesicles 
could be relevant and could work cooperatively to transfer signals through cells within the 
bone marrow. In the next section we will focus on the surface antigen characterization of EVs 
in the peripheral blood of B ALL patients at diagnosis and controls.  
 
 
Flow cytometry characterization of extracellular vesicles in B ALL.   
The importance of communication between tumor cells and their microenvironment through 
the shedding of Extracellular Vesicles (EVs) has been well documented. In leukaemia B-
lymphocytes secrete antigene-presenting vesicles (Raposo et al., in 1996). They found that 
human and murine B-lymphocytes can release exosomes and those had a role in inducing 
antigen specific response. Extra cellular vesicles can be released by CLL blast cells and 
influence with their cargo stromal cells in favor of the leukemogenic process (Ghosh et al., 
2010). The second part of this study was thus focused on the characterization of the EVs 
populations in the PB plasma of B ALL leukemic patients at diagnosis and in control patients. 
For this purpose we choose the flow cytometry approach, which is actually the election 
methodology and allows a rapid identification of membrane antigen and semi quantitate 
definition of EVs populations (Figure 16 A). 
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We were interested in the analysis of EVs CD19 expression, a specific B cell and leukaemia 
marker, in CD61 markers of platels/megakaryocytes and finally in the CD254, which 
represent, the major marker of bone metabolism.  
As reported before in solid tumors and in CLL, the disease progression is associated with an 
increase in the number of EVs in the PB of patients. Ghosh work showed that CLL is 
characterized by an increasing number of EVs CD19+ the far we go with the disease 
progression, whereas the platelets/megakaryocyte CD61 was reduced compared to the healthy 
controls (Figure 18 A-F).   
We used cytoplasmic CFSE dye to mark the total EV populations in PB from patients. We 
then analyzed single populations for their binding ability to selected markers. Finally we 
analyzed and compared double positive populations, in order to understand if bone marker 
CD254 was associated to one of the two populations investigated.    
We expected to have the same conditions described by Ghosh (Ghosh et al., 2010) in our 
pediatric B ALL cohort. However the first observation came from the CFSE population, 
which was overall significantly decreased in patients at diagnosis. CD19+ the most 
represented EVs population in CLL was not the most represented population B ALL, 
suggesting that blasts cells do not produce the large amount of EVs expected. There was 
instead a significant decrease of CD61 population in diagnosis compared to controls as well 
as for CD254 population. The reduced number of CD61 EVs observed at diagnosis, was in 
agreement with Ghosh work. Moreover bone marrow and peripheral blood of leukaemia 
patients at presentation is characterized by low platelets count. If we assume that the CD61+ 
EVs are of platelets origin, this is consistent with the clinical features of leukaemia patients. 
Taken together the data showed that there was a suppressed release of EVs, not restricted to 
CD61 population, but which also involves the CD254 and CD19 groups. The difference with 
Ghosh could be due to the fact that we analyzed an acute phase, rather than a chronic 
condition, in which blasts cells are present for a long period of time. Consistently with the fact 
that CD19 blasts cells do not produce a significant amount of CD19+ EVs we found there 
were no association between EVs production and the blast number at diagnosis. It is clear that 
in this process other cells are involved and we have to keep in to account a possible 
involvement of lymph node and spleen populations. Furthermore we do not exclude the 
possibility that blasts cells can release exosomes, smaller in size and not detectable by flow 
cytometry, which were not studied in this work.  
CD254 bone marker together with CD61 was the most represented population among the ones 
we studied. CD254 is a marker of bone metabolism but it also involved in the B cell 
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development and is expressed by different cell type in specific conditions, as activated T and 
B cells. Megakaryocytes (MKs) also express CD254, and have been shown to be important in 
the bone homeostasis (Beeton et al., 2008; Bord et al., 2010).  
In order to understand if CD254 was specifically associated to one or the other population in 
patients at diagnosis and controls we analyzed double positive populations CD254/CD61 and 
CD254/CD19. Control patients showed that most of the CD61 are also positive to CD254, 
whereas in patients at diagnosis the double positive population was significantly less 
represented. This scenario was similar for CD19/CD254 double positive population. On the 
other side in patients at diagnosis the majority of the CD254 was not associated either to 
CD19 or CD61, suggesting the presence of other parental cells involved in the release of 
CD254+ EVs in the PB.  We know that mature megakaryocytes (CD61+ cells) are involved in 
bone remodeling through the RANKL pathway (Bord et al., 2010). Moreover increasing 
evidence suggests that circulating microparticles expressing CD61 originate predominantly 
from megakaryocytes rather than from platelets (Rank et al., 2011; Flaumenhaft et al., 2009; 
RANK et al., 2010). We suspect that in control patients the majority of CD254/CD61 double 
positive EVs are of MKs origin, and that those might have a role in the bone homeostasis.  
Peripheral blood and bone marrow EVs population in controls patients were also analysed. 
We found that the overall number BM EVs is significantly higher compared to PB. The 
results shows a similar pattern of antigen expression as seen in PB with the difference that all 
the BM EVs populations are much more numerous (Figure 19 A and B).   
With the attempt to gain information about the origin of the CD254/CD61 double positive 
population we assessed if the BM cells of control patients present double positive 
CD254/CD61 cells. Flow cytometry analysis showed that the BM of controls patients was 
characterized by the presence of these cells, potentially involved in the production of EVs that 
we observed in plasma (Figure 20 A-B).  
In conclusion we saw that the PB EVs from patients at diagnosis and controls reflect the bone 
marrow situation. CD254 bone marker was present both in controls and diagnosis. The 
abundance of total EVs population in controls was significantly increased compared to 
leukemic patients at diagnosis. Importantly CD254 was mainly associated to CD61 in controls 
rather than in diagnosis. Unless we expected a predominant CD19+ population at diagnosis 
we found that the EVs blast production was very limited.  
With this study we were able to show that it is possible to isolate EVs from PB of patients at 
diagnosis and to characterize them for their surface antigen markers by flow cytometry.  
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Unexpectedly we found that the EVs production seen in physiological condition is suppressed 
in leukaemia.  
CD254 and CD61 were the most represented populations both in controls and diagnosis.   
Further analyses are required to understand if CD254 EVs population has a physiological 
meaning and thus can have importance in diagnosis or follow up. In view of the data 
described in the previous sections we need to address if CD254 EVs can be produced by 
membrane RANKL expressing blasts. Morover we should investigate which is the functional 
role of these EVs in the bone marrow, if they carry specific cargo and if they have a specific 
tropism. It is known that CD254 EVs can be released by mesenchimal cells and have a 
specific tropism (Cappariello et al., 2015).  
These findings highlight the importance of EVs in the microenvironment and the importance 
of these membrane bodies as carriers of information to distal sites from the parental cells.  
The field of EVs is developing faster. Their role in the pathophysiology of several diseases is 
well described as reviewed by Yoon and collaborators (Yoon et al., 2014). Despite the 
numerous reports on EVs analytical isolation issues, at date standardized precedures for the 
isolation and quantification of EVs are not available. Nonetheless several groups are working 
in this direction and preliminary results for the use of plasma and blood in diagnostic device 
are described, with the final aim to use it directly in lab on chip diagnostic tools.  
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6. Conclusions 
 
The purpose of this study was to understand if leukaemia cells could influence the bone 
marrow microenvironment, acting on osteoclast bone resorbing cells and through the major 
bone metabolism player RANKL. We observed a significantly higher expression of 
membrane RANKL in patients at diagnosis if compared with controls. We found that blasts 
cells from B ALL bone marrow could induce the fusion of PBMC CD14+ osteoclast 
precursor promoting their association in to multinucleate cells. The ability to induce the 
multinucleation was linked to high RANKL expression, and we showed that two patients 
known for their bone lesion at diagnosis expressed high RANKL membrane and were able to 
induce multinucleation.  
Beside this ability to induce multinucleation the GEP analysis revealed that leukemic bone 
marrow is characterized by a significant down regulation of genes that are involved in 
osteoclast differentiation maturation and activation if compared to healthy subjects. The gene 
profile analysis of leukaemia bone marrow resembles that of a hybrid phenotype between a 
defective osteoclast and not fully committed B cell. Leukemic blasts are well described for 
their inability to differentiate into normal B cells, but no information specifically links these 
blast cells to osteoclasts or defective osteoclasts. Cell line FLG29.1 is an example of myeloid 
leukaemia cells that under certain colture conditions can differentiate into fully resorbing 
osteoclasts (Gattei et al., 1992). However data are not available for B cell committed 
leukaemia precursors. FLG29.1 is a myeloid cell line, and the gap between a myeloid cell and 
mature osteoclasts is close, as both come from a common committed progenitor. Less obvious 
is the link between an osteoclast and a B lymphoid committed cell.   
Here we are observing two different aspects of the same disease. On one side the RANKL 
expression on blast cells might represent a more differentiated blast sub population, maybe a 
fraction that is going thorough differentiation. As described by Kato (Kato et al., 2000) 
RANKL induced pre B cells to proliferate after an inhibition at the G1 phase, thus moving on  
through their differentiation.  
On the other side we have the osteoclastic like “suppressed” background, highlighted by the 
GEP that could represent a step before, when the switching from myeloid lineage and B 
compartment is altered.  
Literature is a source of precious information of this phenomenon. The transcription factor 
Pax5 is a common regulator of B lymphoid differentiation and osteoclasts precursor as well. 
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At B cell commitment Pax5 represses diverse biological activities including receptor 
signaling, cell adhesion, migration and transcriptional control and cellular metabolism.  
Pax5-/- pro B cells and common lymphoid progenitors display lymphoid and myeloid lineage 
promiscuity of gene expression. Among gene repressed by Pax5 at the pro B cells there are 
RANKL and MCS-F R. In Pax5-/- cells factors as RANKL, which continue to be expressed, 
may support deregulated osteolysis as RANKL expression can stimulate OCs activity.  
We think that at early stage of leukaemia the mechanism involved in switching off myeloid 
specific genes and in switching on B cell specific patterns could be compromised.  
In osteopetrotic mice as in IL7-/- mice the transition between pro and pre B is blocked, 
leading to a reduced B cell numbers, as it is described for oc/oc mice. Moreover there is a 
concomitant increase in myelopoiesis with a high number of inactive OCs (Schlissel MS, 
Corcoran LM et al., 1991; Gilliland DG, Griffin JD., 2002). 
Although the differentiation pathways for lymphoid and myeloid lineage are mutually 
exclusive, there is a certain degree of plasticity, and B220+ cells isolated from murine bone 
marrow are able to differentiate in vitro into osteoclasts (Manabe et al., 2001). 
Osteopetrotic models showed accumulation of a bone marrow population that is B220+ 
CD11b+. In vitro the treatment of IL7 induced the differentiation of B220+ CD11b+ cells into 
B lymphocytes through the induction of Pax5 and the inhibition of myeloid markers with 
partial restoration of the B cell population and thus of the B lymphopoiesis (Blin-Wakkach et 
al., 2006). A model of mild inducible osteopetrosis is recreated by Zoledronic Acid (ZA) 
treatment as described by Monsour (Monsour et al., 2011). Using this system they were able 
to study the effects of the inducible bone marble phenotype on stromal cells included 
osteoblasts. They showed an indirect effect that altered the expression of CXCL12 and IL-7 
decrease by stromal cells and associated with reduced osteoblastic engagement. ZA induced 
disadvantageous condition for B lymphopoiesis leading to the retention of B cell progenitors 
outside of their bone marrow niches. These effects were not directly (Mansour et al., 2001). 
Figure 21 summarizes the possible scenarios that RANKL membrane expression could cause 
in different B ALL leukemia subtypes. 
In conclusion the growing skeleton in leukaemia is vulnerable and it is more sensitive to 
osteotoxic therapy. Early recognition and intervention strategies are essential, and in this 
context the deep knowledge of B lymphopoiesis and osteoclastogenesis shared pathways are 
important to anticipate diagnosis and to prevent long-term sequelae from altered bone 
metabolism.          
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Figure 21: Model and hypothesis of RANKL expression in B ALL subtypes. (A) RANKL 
membrane expression on B ALL common could induce pre OCs to multinucleate and activate 
their resorption activity. (B) B ALL and Pre B with low RANKL expression might be forced 
to move on through proliferation and differentiation to pre B and to immature B stage by 
inducing RANKL expression. (C) More immature B ALL forms or MLL could be pushed 
through osteoclastic like differentiation by exogenous RANKL and MCS-F stimulation.  
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